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ABSTRACT
EVALUATING THE EFFECTS OF FASTING CONDITIONS IN COMBINATION WITH
TEMOZOLOMIDE FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME

By
Joseph Duffy
Glioblastoma multiforme (GBM) is the most aggressive type of glioma and most lethal of adult
brain tumors. The standard of care for GBM is maximal surgical resection followed by adjuvant treatment
with the chemotherapeutic agent temozolomide (TMZ) and radiotherapy. The presence of TMZ-resistant
cells in GBM that can reverse the TMZ induced cytotoxic lesions by expressing MGMT contribute to
therapy resistance. A common trait of cancer is an altered carbohydrate metabolism. Known as the
Warburg effect, cancer cells will preferentially oxidize glucose to lactate in glycolysis. This less effective
pathway of ATP production per mole of glucose means cancer cells must uptake significantly greater
amounts of glucose to sustain physiological needs. One method that directly targets the bioavailability of
glucose is fasting. Fasting lowers systemic glucose levels, lowers anabolic hormone levels (insulin and
IGF-1), and elevates ketone bodies like ß-hydroxybutyrate (ß-HB). This study sought to evaluate the
effects of fasting in combination with TMZ on viability of GBM cell lines LN229 and T98G, and normal
astroglial cell line SVG p12. The data from showed that glucose restricted media significantly enhanced
the cytotoxic effects of TMZ in LN229 and T98G cells, while having no effect in SVG p12 cells. ß-HB in
combination with TMZ potentiated the cytotoxicity of TMZ in LN229 and T98G cells, while reducing the
cytotoxicity of TMZ in SVG p12 cells. Western blot analysis for MGMT determined T98G cells were
the only cell line to express MGMT. Both glucose restricted media and ß-HB supplemented media in
combination with TMZ significantly decreased the expression of MGMT levels in T98G cells. Together,
this initial evidence suggests fasting may be a useful method to selectively increase cytotoxicity of TMZ
in GBM cells, while protecting normal cells. Future research is needed to further assess the potential of
fasting as an adjuvant therapy in the treatment of GBM.
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INTRODUCTION
Gliomas are the most common primary tumor of the brain.1 Gliomas arise from accumulation of
mutations in glial cells of the brain. Glioblastoma multiforme (GBM) is the most aggressive type of
glioma, classified by the World Health Organization as a grade IV glioma.2 The standard of care for GBM
is maximal surgical resection of the tumor followed by adjuvant treatment with the chemotherapeutic
agent temozolomide (TMZ) and radiotherapy. Despite these treatments, the rate of recurrence is ~90%
with a median overall survival (OS), the length of time after resection of the disease the patient remains
alive, of 15 months.3
TMZ is an orally administered prodrug that readily crosses the blood brain barrier and is the
standard of care chemotherapeutic agent for GBM.3 TMZ is an alkylating agent that adds a methyl group
on various bases of DNA, subsequently leading to base pair mismatch during DNA replication. These
mismatches activate futile DNA repair mechanisms that ultimately leads to cell death. However, GBMs
contain cells that are resistant to the TMZ induced cytotoxic lesions through expression of the DNA repair
protein O6-methyl-guanine-DNA methyltransferase (MGMT).4–7 There is a direct correlation between
TMZ resistance and MGMT methylation status.4,6 Thus, further investigation into sensitization of TMZresistant cells is needed.
A common trait of cancer is the dysregulation of carbohydrate metabolism. First described in
1925 by Otto Warburg, cancer cells preferentially oxidize glucose to lactate in glycolysis, inhibiting
mitochondrial respiration.8 Now known as the “Warburg effect”, this less effective pathway of ATP
production demands that cancer cells must uptake and oxidize significantly more molecules of glucose to
meet physiological needs. GBM oxidizes significantly more glucose than normal brain tissue.9 Glucose
transporters (GLUT) 1 and 3 are significantly upregulated in GBM relative to lower grade tumors.10
Glycolysis and the Warburg effect also provides cells with intermediates needed for biosynthesis.
Glycolysis provides glucose 6-phosphate, glyceraldehyde 3-phosphate, and 3-phosphoglycerate, used to
synthesize ribose sugars for nucleotides, glycerol in lipids, and nonessential amino acids respectively.11
1

Upregulation of key glycolytic enzymes, such as hexokinase (HK) and lactate dehydrogenase A (LDHA)
is seen in GBM compared to normal brain tissue and lower grade gliomas.9,12,13 Knockdown of HK-214
and LDHA37 have both been shown to augment the efficiency of TMZ in human GBM cell lines.
Furthermore, multiple studies have identified hyperglycemic events during therapy as an unfavorable
prognostic cofactor for OS in GBM patients.15,16,17–19 Thus, systemic restriction of carbohydrates could
serve as a useful treatment for GBM.
One method to restrict available carbohydrates is fasting. Originally investigated for the treatment
of epilepsy in 1921, fasting has since been investigated for its effects in many diseases, including
cancer.20 Fasting increases the life span of rodents up to 60%, while also delaying the onset of many age
related diseases.21,22 Short-term fasting (72 hours) leads to significant reduction in plasma glucose levels.
This fall in blood glucose is met with changes in hormonal signals, such as systemic reduction in insulin
and insulin-like growth factor, increase in glucagon, and increase in epinephrine levels.23 Although the
changes in hormonal signals appear to be involved in the cellular responses, the precise molecular
mechanisms of fasting are not completely understood, but are undeniably multifactorial.
Energy allocation during fasting appears to be fundamental. That is, given a certain amount of
energy at any given time, normal cells must reallocate energy between growth/replication and
maintenance/repair/survival. Under fasting conditions, normal cells respond to the change in energy by
reinvesting energy towards maintenance/repair/survival.24–27 Cancer cells on the other hand harbor
oncogenic mutations that promotes self-sufficient growth and uncontrolled cell division independent of
current energy availability. This differential stress response begins to explain why nutrient deprivation
and fasting conditions have been shown to protect normal cells while sensitizing cancer cells to
chemotherapy.28,29 Glucose restricted media has been shown to enhance the response of GBM cell lines to
TMZ, with no difference in cell death noted in a primary glia cell line subjected to restricted glucose
media and TMZ treatments.30 Furthermore, fasting in combination with TMZ reduced tumor volume, and
increased OS of GBM bearing rodents, with significant reduction in blood glucose and IGF-1 levels seen
2

in fasted subjects.30 However, changes in blood glucose and hormonal signals are not the only responses
initiated by fasting, and glucose is not the only hepatically produced and systemically released metabolite
during fasting conditions.
The brain preferentially uses glucose as fuel, using up to 60-70% of the total body glucose
requirements. During fasting when glucose levels are decreased, the brain begins to utilize ketone bodies
(KB). KB are water soluble molecules synthesized by the liver and systemically released during fasting.
During fasting, Fatty acids (FAs) are transported to the liver where they are oxidized to acetyl-CoA.
Acetyl-CoA serves as the starting material for KB synthesis, where three acetyl-CoA molecules condense
in a series of reaction to eventually form the KB β-hydroxybutyrate (β-HB). β-HB is released into
circulation where it can be utilized as an energy source for the heart, skeletal muscle, kidney, and
brain.31–35 Once in the cells of brain, β-HB is cleaved to form two molecules of acetyl-CoA in a series of
reactions catalyzed by 3-hydroxybutyrate dehydrogenase (BDH1), 3-oxoacid-CoA transferase (OXCT1),
and acetyl-CoA acetyltransferase (ACAT1). Unlike normal brain tissue, GBM tissue expresses low levels
of OXCT1 and BDH1.36 Furthermore, β-HB has been previously shown to have inhibitory effects on
histone deacetylase 1 (HDAC-1).37–39 HDACs are nuclear enzymes that function in epigenetic
modifications through chromatin remodeling. Interestingly, HDAC-1 is found to be overexpressed in
GBM compared to normal brain tissue.40 Furthermore, HDAC inhibition by β-HB augmented the
cytotoxic efficiency of TMZ in TMZ-resistant GBM cells.41 Thus, β-HB production during fasting could
have additional anti-tumor effects that slows growth and sensitizes GBM to TMZ.
This study sought to explore the effects of fasting in combination with TMZ in human GBM Cell
lines, we hypothesize that exposure to fasting conditions (glucose restricted and β-HB supplemented
culture medium) will further potentiate cell death of GBM cells compared to either treatment alone.
Furthermore, this study sought to explore the effect of fasting conditioned media in combination with
TMZ in a normal glial cell line. A secondary goal of this study was to determine whether changes seen
between fasting conditions and normal conditions were due to changes in the expression of MGMT, the
3

highly characterized gene involved in TMZ resistance. Should fasting effectively enhance the efficiency
of TMZ in GBM cells while sparing normal brain cell cells, it may warrant further investigation in order
to improve treatment efficiency in GBM.
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CHAPTER 1: LITERATURE REVIEW
Introduction
Glioblastoma multiforme (GBM) is the most aggressive type of glioma and most lethal of adult
brain tumors. The standard of care for GBM is maximal surgical resection of the tumor followed by
adjuvant treatment with the chemotherapeutic agent temozolomide (TMZ) and radiotherapy. However,
GBM contains TMZ-resistant cells that contribute to repopulation of the tumor and recurrence of disease.
A hallmark of cancer is the presence of altered carbohydrate metabolism. The Warburg effect describes
the process by which cancer cells preferentially oxidize glucose to lactate in glycolysis, even in the
presence of oxygen. This less efficient method of ATP production per glucose molecule means cancer
cells must uptake significantly more glucose to meet physiological needs. Fasting is a recently emerging
practice that has been shown to have beneficial effects in cancer therapy, although the mechanism of
action is not completely understood. This chapter highlights the mechanism of action of TMZ, the
Warburg effect in GBM, and the systemic changes that occur during fasting, with emphasis on the overlap
of these different areas of research.
Temozolomide: Mechanism of action, DNA repair mechanisms, and cellular resistance.
Temozolomide (TMZ) is an orally administered prodrug that readily crosses the blood brain
barrier and is the most commonly used chemotherapy agent for GBM.3 TMZ is a monofunctional DNA
alkylating agent that is stable in an acidic environment, but is labile above pH 7. Following absorption,
TMZ is rapidly degraded under physiological pH to the active alkylating agent 5-(3-methyltriazen-1-yl)
imidazole-4-carboximide (MTIC).42 MTIC reacts with water and breaks down to form 5-aminoimidazole4-carboxamide (AIC) and a methyldiazonium cation. The highly reactive methyldiazonium cation acts as
a nonspecific alkylating agent that methylates DNA purinic bases at N7-guanine (70%), N1-adenine (1215%), N3-methyladenine (10%), and O6-guanine residues (6-8%).42,43 Methylation at N7-guanine, N1adenine, and N3-adenine are accountable for the majority of methyl adducts. However, they are not
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responsible for cytotoxic effects for they are readily repaired by the base excision repair (BER) system. It
is the DNA mismatch repair (MMR) processing of the O6- methylguanine (O6MeG) lesions that is
responsible for the cytotoxic effects of TMZ.
During DNA replication, TMZ induced O6MeG in the template strand is mispaired with thymine
(T) in the daughter strand, alerting MMR system (Figure 1).44,45 MMR is a highly conserved DNA repair
system that repairs DNA base mismatches in the daughter strand created during DNA replication. In
MMR, base mismatches are recognized by the heterodimeric complex consisting of MSH2 and MSH6.
MSH2-MSH6 recruits another complex between MLH1 and PMS2 to initiate the MMR process. MMR
excises T from O6MeG -T in the daughter strand. However, the O6MeG persists in the template strand,
and subsequent mispairing of O6MeG with another thymine leads to repetitive rounds of MMR
processing.46 These futile rounds of MMR processing and repair generates DNA double stranded breaks
(DSBs) during the late S/G2 phase of the cell cycle.45–48 Accumulation of DSBs triggers G2/M phase cell
cycle arrest and late caspase activation.45 Thus, the cytotoxic effects of TMZ are due to the accumulation
of double stranded breaks in the DNA that arrests the cell in the G2/M phase of the cell cycle, and
ultimately induce apoptosis.43–46,49,50,50 Unfortunately, “Multiforme” describes the heterogeneous
population of cells that are present within GBM, and cytotoxicity to TMZ is not equal in all cells lineages.
A population of TMZ-resistant cells has been identified in GBM that are able to reverse the TMZ
induced cytotoxic lesions by expressing the DNA repair protein O6-methyl-guanine-DNA
methyltransferase (MGMT) (Figure 1). MGMT functions by demethylating O6MeG, reversing TMZ
mechanism of action, and contributing to chemoresistance.4–7 Furthermore, a direct correlation has been
identified between TMZ resistance and the methylation status of MGMT.4,6 These cells contribute to
repopulation of the tumor and recurrence of disease. Thus, further investigation into sensitization of
TMZ-resistant cells is needed.
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Figure 1. Temozolomide (TMZ) mechanism of action and cellular repair mechanism. TMZ methylates DNA
purinic bases at N7-guanine, N1-adenine, N3-methyladenine, and O6-guanine residues. N7MeG, N1MeG, N1MeA, and
N3MeA are non-cytotoxic residues for they are readily repaired by the base excision repair (BER) system. O6methyl-guanine-DNA methyltransferase (MGMT) expressed by cells readily removes the methyl group from
O6MeG, contributing to cell survival and TMZ resistance. Only in MGMT negative cells does O 6MeG persist in the
DNA, where it is mispaired with thymine during DNA replication. This alerts the mismatch repair (MMR) system
which excises thymine from the daughter strand of DNA. However, MMR fails to remove the methyl group so
O6MeG persists in the template strand. This induces a futile MMR cycles that causes double-stranded breaks (DSBs)
in the DNA, leading to late caspase activation and apoptosis.
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The Warburg Effect in Cancer and Its Role in GBM
A common trait of cancer is the presence of altered carbohydrate metabolism. The metabolic
dysregulation of cancer cells was first discovered in 1925 by Otto Warburg.8 Warburg showed that even
in the presence of oxygen, carcinoma cells preferentially oxidize glucose to lactate in glycolysis,
inhibiting mitochondrial respiration. Now known as the “Warburg effect”, this less effective pathway of
ATP production per glucose molecule demands that cancer cells must take up and oxidize significantly
more molecules of glucose to meet physiological needs. Glucose transporters (GLUT) are transmembrane
proteins that facilitate the translocation of glucose across the cell membrane. In the brain, GLUT1 &
GLUT3 serve as the main neuronal glucose transporters.51–55 Through real-time quantitative reverse
transcription polymerase chain reaction (RT-qPCR) analyses, one study found GLUT1 and GLUT3 to be
upregulated in GBM relative to lower grade brain tumors, and extent of GLUT3 expression was found to
be directly correlated to decreased OS.10 Another research group found that long term treatment of human
GBM cell lines T98G and U373 with TMZ increased the expression of GLUT3, suggesting a correlation
between glucose uptake and acquired TMZ resistance.56 However, the Warburg effect is not exclusive to
cancer cells, and similar method of aerobic glycolysis has been shown to occur in proliferating
lymphocytes, macrophages, and pluripotent embryonic stem cells.57–60 Looking only at the rate of ATP
production, the Warburg effect is much less energetically favorable than oxidative phosphorylation, so
why do cancer, and proliferating cells, experience the Warburg effect?
One explanation for the use of the Warburg effect is it provides cells with intermediates needed
for biosynthesis. Following glucose transport into the cell, glucose is converted to glucose 6-phosphate
(G6P) by hexokinase (HK) in the first step of glycolysis. G6P is important intermediate in the pentose
phosphate pathway for the synthesis of ribose sugars, crucial components of nucleic acids. While HK-1 is
the primary isoform found in the brain, gene set enrichment analysis of 25 GBM patients and 10 normal
brains showed HK-1 to be significant downregulated and HK-2 significantly upregulated in GBM
compared to normal brain tissue.12 A related study demonstrated that short hair-pin RNA (shRNA) knock
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down of HK-2 decreased production of lactate and increased sensitivity to TMZ in U87 and U373 GBM
cell lines.14 In addition to ribose, intermediates in the glycolytic pathway such as glucose 6-phosphate,
glyceraldehyde 3-phosphate, and 3-phosphoglycerate can be used in the biosynthesis of glycogen,
glycerol for lipids, and nonessential amino acids (serine, glycine, cysteine, etc.) respectively. 11
The final step in the Warburg effect is the conversion of pyruvate to lactate catalyzed by lactate
dehydrogenase A (LDHA). Although once thought of as an unusable byproduct of aerobic glycolysis,
lactate has been shown to stimulate angiogenesis, promote migration, and contribute to immune
evasion.61–64 The presence of the Warburg effect has been identified in GBM through evaluation of the
fermentation of glucose to lactate. Analysis of pyruvate/lactate ratios revealed a 300% increase in
glycolytic fermentation in GBM compared to non-neoplastic brain tissue.9 Immunohistochemistry (IHC)
analysis of 9 grade IV (GBM), 7 grade III, and 10 grade II gliomas found LDHA expression to be
significantly higher in grade IV (P<0.005) compared to the grade II samples.13 Additionally, small
interfering RNA (siRNA) silencing of LDHA has been demonstrated to inhibit proliferation and induce
apoptosis in a variety of GBM cell lines13,65. Furthermore, both siRNA knockdown of LDHA and LDHA
inhibitors were able to augment the efficiency of TMZ in GBM cell lines compared to TMZ alone.13,65
These study allude to the importance of the Warburg effect in GBM growth and therapy resistance.
If glucose consumption promotes tumor growth and contributes to therapy resistance, then
systemic glucose concentrations might be correlated to progression of disease and overall survival (OS).
A group of researchers from Mainz, Germany conducted a retrospective analysis on the effect of
hyperglycemic events (blood glucose levels >10 mM) on OS during adjuvant therapy of 106 GBM
patients. They concluded that patients who experience one or more hyperglycemic events had a 48.2%
decrease in median OS (8.8 months) compared to patients who experience ≤ 1 such events
(16.6 months).15 A similar study of 191 GBM patients found that patients with mean blood glucose levels
of >7.6 mM had a 37% decrease in median OS (9.1 months) compared to patients with mean glucose
levels of <5.2 mM (14.5 months).16 Similar results supporting hyperglycemic events as an unfavorable
9

prognostic cofactor for OS has been shown in a multitude of other studies.17–19 Thus, systemic restriction
of carbohydrates could serve as a useful treatment for GBM.
Fasting: Systemic Changes and Role in Cancer Therapy
The clinical relevance of fasting was first investigated for the treatment of epilepsy in 1911.66
They described seizures of lesser severity in patients who fasted compared to non-fasting epileptic
patients. In the years since this observation, intermittent fasting has been the focus of many studies for its
effects on cardiovascular disease, epilepsy, diabetes, depression, obesity, and cancer.24,31,67–70 In a fed
state, insulin and insulin-like growth factor 1 (IGF1) are produced by the liver and systemically released
where they bind to insulin receptor (IR) and insulin-like growth factor 1 receptors (IGFR-1) on the extrahepatic cells respectively. IGFR-1 is a receptor tyrosine kinase that regulates not only glucose metabolism
but cell growth via the downstream RAC-alpha serine/threonine-protein kinase (AKT)/mammalian target
of rapamycin complex 1 (mTORC1) pathway. Low blood glucose events due to fasting is detected by the
pancreas, causing a reduction in the production of insulin, reduction in insulin-like growth factor (IGF),
and an increase in the production of glucagon and epinephrine.71 A study on the effects of fasting and the
concentration of glucose, insulin, and counter regulatory hormones in healthy individuals found that 72
hours of fasting decreased insulin levels from 421 pM to 127 pM, increased glucagon from 10 pM to 23
pM, and increased epinephrine levels from 8.4 ng/L to 20.9 ng/L.23 Plasma glucose levels fell from 93.7
mg/dL to 66.63 mg/dL after 2 days of fasting, and remained stable for the remainder of the fast.23 This
observation can be explained by the liver’s response to changes in hormonal signals under nutrient
deprived conditions. Under these conditions, glucagon and epinephrine signaling triggers glucose
production in the liver via gluconeogenesis (figure 2). Glucagon signals the breakdown of glycogen to
glucose 6-phosphate in the liver. Glucose 6-phosphate is hydrolyzed in the liver to form glucose that is
systemically released to serve as fuel for the body.72 Once hepatic glycogen levels have been depleted,
glucogenic amino acids are converted by the liver into citric acid cycle (TCA) intermediates and used to
make glucose. Normal cells rely on these signals for reallocating energy between growth/reproduction
10

and maintenance/repair/survival. Under fasting conditions, cells respond to the change in the regulatory
signals by reinvesting energy towards maintenance/repair/survival.24–27 Cancer cells on the other hand
harbor oncogenic mutations that promotes self-sufficient growth and uncontrolled cell division
independent of systemic growth hormone signaling.

Figure 2. Systemic changes induced by fasting. The body responds to fasting conditions by the systemic release of
catabolic hormones glucagon, epinephrine, and cortisol. Drop in blood glucose levels is detected by the pancreas
which by releasing glucagon. Cortisol signaling from the adrenal glands mobilizes fatty acids by activating hormone
sensitive lipase (HSL) to breakdown triacylgltriaycerides (TAG) in adipose tissue. Epinephrine released by the
adrenal gland stimulates proteolysis in skeletal muscle. Glucagon signaling in the liver stimulates gluconeogenesis
and ketogenesis. Hepatic uptake of amino acids from skeletal muscle are used along with glycerol as the starting
material for gluconeogenesis. ß-oxidation of fatty acids in the liver yields acetyl-CoA, which is used as the starting
material for the synthesis of ketone bodies. Both glucose and ketone bodies are released systemically to act as
energy sources for the rest of the body.73
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Due to mutations in growth signaling genes in cancer, nutrient deprivation and fasting conditions
have been shown to protect normal cells while sensitizing cancer cells to chemotherapy. A study
investigating the response of normal rat glial cells cultured in glucose restricted media (0.5 g/L) and
exposed to a high dose of the alkylating agent, cyclophosphamide (12 mg/mL), reported glucose
restriction significantly decreased cyclophosphamide cytotoxicity (80% survival) compared to rat glial
cells cultured in 1.0 g/L glucose (20% survival).28 Interestingly, the same dose of cyclophosphamide
combined with glucose restricted media did not affect the cytotoxicity in two of three rat glioma cell lines
(C6 and A10-85), a human glioma cell line (LN229), and a human neuroblastoma cell line (SH-SY5Y ).
Cytotoxicity in the third rat glioma cell line (RG2) was significantly increased cyclophosphamide
treatment under restricted glucose conditions.28 This same study also investigated the effect of high dose
treatment of etoposide in fasted mice. Etoposide is a chemotherapy agent used for the treatment of
testicular cancer, small cell lung cancer, and neuroblastoma.74 DNA topoisomerases II are essential
enzymes to DNA replication that functions to relieve mechanical stress produced during DNA replication.
Etoposide forms a complex with topoisomerase II and DNA, leading to inhibition of topoisomerase II and
the subsequent generation of double stranded breaks.75 The study reported that while treatment with a
high dose of etoposide (100 mg/kg body weight) was lethal to 56% of ad-lib fed mice, no casualties were
seen in mice who fasted 48 hours before treatment with the same dose of etoposide.28 Another extensive
study by Changhan Lee et al., 2010 looking at the effects of fasting in combination with chemotherapy
agents (doxorubicin or cisplatin) found that mice fasted for 48 hours (complete food withdrawal with
water access) had a 50% reduction in tumor volume and an increased OS compared to ad-lib fed mice
harboring murine melanoma, breast, neuroblastoma, and glioma tumors. To identify gene expression
patterns associated with fasting conditions, they conducted genome-wide microarray analysis of nonneoplastic liver, heart, skeletal muscle, and subcutaneous 4T1 breast tumor tissue from mice previously
fasted. They found that fasting differentially regulates proliferation-associated genes, such as insulin
signaling adaptor, mitogen-activated protein kinase 6, homeobox protein TGIF1, eukaryotic translation
initiation factor 4E-binding protein 1, cyclin-dependent kinase inhibitor 1, and p53-regulated protein
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PA26, in which downregulation was seen in non-neoplastic tissue. Either up regulation or no change in
expression was seen in the breast cancer tissue for the same genes. In order to determine a possible
mechanism by which fasting augments chemotherapy (with cisplatin) and reduces tumor progression,
Changhan Lee et al., 2010 cultured melanoma (B16 cells) and breast (4T1 cells) in growth medium
mimicking glucose concentrations in the ad lib-fed (2.0 g/L glucose) or fasting mice conditions (0.5 g/L
glucose). Traditional cell culture medium is supplemented with 10% fetal bovine serum (FBS). In order to
mimic the fasting induced reduction of growth factors like IGF-1 and insulin, all cell medium also
contained 1% FBS. Following exposure to cisplatin (8 mM), a 20-fold increase in DNA damage was seen
in both 4T1 and B16 cells exposed to fasting glucose concentrations compared to ad-lib glucose
concentrations.29 This study demonstrated the differential stress response produced by fasting, protection
of normal cells while sensitizing cancer cells to chemotherapy. However, changes in blood glucose and
hormonal signals is not the only response initiated by fasting, and glucose is not the only hepatically
produced and systemically released metabolite during fasting conditions.
The brain preferentially uses glucose as fuel, using up to 60-70% of the total body glucose
requirements. When glucose levels are decreased, the brain begins to utilize ketone bodies (KB) as fuel.
KB are constitutively synthesized by the liver, detectable at micromolar levels (0.1-0.2 mM). However, in
response to 48 hour fasting, KB serum concentrations can reach levels of 1-2 mM and upwards of 6-8
mM during prolonged starvation.34 KB are water soluble molecules synthesized by liver and systemically
released to serve as fuel for the heart, skeletal muscle, kidney, and brain.31–35 Low insulin/IGF-1, and
elevated glucagon, epinephrine, and cortisol signaling triggers the mobilization of fatty acids (FAs) from
adipose tissue. Once systemically released, FAs are transported to the liver are subsequently oxidized to
form acetyl-CoA, the starting material for ketone body synthesis (figure 2). In the liver, two acetyl-CoA
condense to form acetoacetyl-CoA. Acetoacetyl-CoA is condensed with another acetyl-CoA molecule to
form ß-hydroxy-ß-methylglutaryl-CoA (HMG-CoA). Subsequent cleavage of HMG-CoA by HMG-CoA
lyase forms the first ketone body, acetoacetate. Acetoacetate is reduced by β-hydroxybutyrate
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dehydrogenase to form the ketone body β-hydroxybutyrate (β-HB). The conversion of acetoacetate to βHB has two important functions. First, it stores a NADH energy equivalent that will be used by
extrahepatic cells. Second, being that acetoacetate is a β-ketoacid, it is vulnerable to decarboxylation into
the volatile waste product acetone. By converting acetoacetate to β-HB, a more stable molecule is
produced that can be exported into circulation.73 Once in circulation, β-HB enters the brain through
monocarboxylate transporter 1 and 2 (MCT1/2) expressed on the blood brain barrier.76 Once in the brain,
β-HB is oxidized back in the mitochondria to acetoacetate by 3-hydroxybutyrate dehydrogenase (BDH1),
generating a molecule of NADH. Acetoacetate is activated by a transfer of CoA from succinyl-CoA by 3oxoacid-CoA transferase (OXCT1), which is then cleaved by acetyl-CoA acetyltransferase 1 (ACAT1) to
form two acetyl-CoA molecules to be used in energy production via TCA. However, β-HB is
differentially utilized by normal and neoplastic brain tissue, and β-HB has additional inhibitory effects on
class I histone deacetylase (HDAC) proteins.
GBM tissue has been shown to express low levels of enzymes involved in KB metabolism, OXCT1
and BDH1. IHC Analysis of 17 GBM specimens revealed low (5-20% of tumor cells) or very low (> 5%
of tumor cells) expression of OXCT1 in 14 of 17 GBM samples. This same study found BDH1
expression to be either low or very low in all 17 GBM samples.36 β-HB has previously been shown to act
as an inhibitor of HDAC-1.37–39 HDACs are nuclear enzymes that function in chromatin remodeling
through the deacetylation of chromatin. Class I HDAC have previously been demonstrated to be
overexpressed in GBM compared to normal brain tissue.40 Additionally, inhibition of class I HDAC by a
variety of HDAC small molecule inhibitors significantly reduced proliferation of U87, LN18, and patient
derived GSC cell lines.40,77 Furthermore, HDAC inhibition by β-HB was shown to sensitize TMZresistant GBM cells to TMZ.41 Thus, β-HB production during fasting could have additional anti-tumor
effects that slows growth and sensitizes GBM to TMZ.
Fasting has been shown to enhance the response of GBM to TMZ both in vivo and in vitro. As
proof of concept, one study found a three-fold lower TMZ half maximal inhibitory concentration (IC50)
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value when A172, U251, and LN229 human GBM cell lines, and C6 and GL26 rat GBM cell lines were
exposed to glucose restricted media (0.5 g/L glucose) compared to normal glucose media (2.0 g/L).30
Additionally, no difference in cell death was noted in the primary glia cell line when subjected to
restricted glucose in combination with TMZ.30 This same study then monitored the response in vivo using
luciferase firefly gene expressing GL26 (GLS6luc) murine cell line implanted intracranially in the right
frontal lobe of C57BL/6 mice. Six days post implant, mice were subjected to 48 hours of short-term
starvation (STS) with TMZ administration (15 mg/Kg) at 24 and 48 hours of STS. They found that STS in
combination with TMZ significantly reduced tumor volume compared to the control and either treatment
alone (p<0.05).30 Additionally, OS was slightly increased, with one subject alive 80 days after tumor
implantation (p<0.05).30 In order to mimic the oncologic treatment conditions of human patients, they
tested the effects of multiple chemotherapy and fasting cycles. Four days post GL2luc intracranial
implantation, mice were subjected to STS for 48 hours with administration of TMZ at 24 and 48 hours.
Food was implemented days 6-9 before a second 24 hour fast followed by a second cycle of TMZ
treatment. OS was significantly increased in STS + TMZ group compared to TMZ alone and control
groups (p<0.01). Furthermore, OS was increased compared to mice who received a single dose of
TMZ/STS, suggesting that the additional second cycle of TMZ and STS can further delay morbidity.30
This study also monitored the effects of STS alone, TMZ alone, and STS + TMZ has on blood glucose
and IGF-1 levels. Following 48 hours STS, a 70% reduction in blood glucose was seen in both STS and
STS + TMZ groups compared to control group, with no difference seen TMZ alone compared to control
group. Furthermore, STS + TMZ showed a 60 % decrease in systemic IGF-1 levels compared to TMZ
alone.30 The drop in both glucose and IGF-1 was thought to be a contributor to how STS further sensitizes
GBM cells to TMZ. Further investigation is needed to determine whether the multifactorial changes that
occur during fasting can augment the efficiency of TMZ in GBM. In accordance with any new therapy,
proper measures must also evaluate the effect of fasting in combination with TMZ on normal cells to
prevent unintended effects and assure fasting as a safe practice.
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Conclusion
TMZ is the standard chemotherapy agent used for the treatment of glioblastoma multiforme.
However, due to the presence of TMZ-resistant cells that can reverse the TMZ induced cytotoxic lesions
by expressing MGMT, reoccurrence of disease is inevitable. A common trait of cancer is an altered
carbohydrate metabolism. Known as the Warburg effect, cancer cells will preferentially oxidize glucose
to lactate in glycolysis, inhibiting mitochondrial respiration. This less effective pathway of ATP
production per molecule of glucose means cancer cells must uptake significantly greater amounts of
glucose to sustain physiological needs. One method that directly targets the bioavailability of glucose is
fasting. Short term fasting (72 hours) lowers systemic glucose levels, lowers anabolic hormone levels
(insulin and IGF-1), and elevates ketone bodies like ß-HB. Normal cells respond to this change in glucose
bioavailability by reinvesting energy towards repair/maintenance/survival. However, cancer cells harbor
oncogenic mutations that impair their ability to adjust to these changes. This differential response to
nutrient deprivation and fasting conditions has been shown to protect normal cells while sensitizing
cancer cells to chemotherapy. While the potential for the use of fasting in combination with chemotherapy
for the treatment of cancer is supported by the literature, studies evaluating the effect of fasting in
combination with TMZ for GBM is minimal. Studies designed to shed light on the effects fasting in
combination with TMZ has on cell viability and expression of MGMT in GBM cells is needed to help
evaluate its potential as a therapeutic agent for the treatment of GBM.

16

CHAPTER 2: HYPOTHESIS AND AIMS.
As suggested in the literature, the effects of fasting have been shown to lower systemic blood
glucose and IGF-1/insulin production while increasing ketone body production. Previous in vitro analysis
of glucose restriction, serum restriction, and ketone body supplementation in combination with TMZ has
been shown to protect normal glial cells while increasing sensitivity of GBM cells. Thus, fasting induced
systemic effects prior to treatment may assist in augmenting the efficiency of chemotherapy, while
helping to protect normal cells against the cytotoxic effects of chemotherapy.
The purpose of this study is to evaluate the effects fasting conditions in combination with TMZ in
human GBM cell lines. I hypothesize that exposure to physiological fasting conditions (glucose restricted
and β-HB supplemented culture medium) prior to, and during TMZ treatment further potentiates cell
death of GBM cells compared to either treatment alone or control groups. Additionally, I hypothesize that
prior exposure to fasting conditions will protect normal glial cells against cytotoxic effects of TMZ.
I will use 3 specific aims to evaluate this hypothesis.
Aim 1: To test the cytotoxicity of LN229 GBM cells, T98G GBM cells, and SVG p12 astroglial
cells exposed to glucose restricted media in combination with TMZ. Following a 24 hour exposure to
either glucose restricted media (0.5 g/L glucose) or normal glucose media (2.0 g/L), I will treat cells with
varying doses of TMZ for an additional 96 hours and perform cytotoxicity assay using CellTiter-Glo® 2.0
Cell Viability Assay and CellQuanti-Blue™ cell viability assay kit.
Aim 2: To test the cytotoxicity of LN229 GBM cells, T98G GBM cells, and SVG p12 astroglial
cells exposed to ß-HB supplemented media in combination with TMZ. Following a 24 hour exposure to
either glucose restricted media plus ß-HB (0.5 g/L glucose) or normal glucose media plus ß-HB (2.0 g/L,
2 mM β-HB), I will treat cells with varying doses of TMZ for an additional 96 hours and perform
cytotoxicity assay using CellQuanti-Blue™ cell viability assay kit.
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Aim 3: Determine if changes in cytotoxicity are due to a change in the expression of MGMT.
MGMT expression will be determined via immunoblotting using cells exposed to TMZ alone or in
combination with glucose restricted media and fasting conditioned media.
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CHAPTER 3: CULTURE AND MAINTENANCE OF CELL LINES.

Introduction
Human cell culture has long been used as significant tools in cancer research. The first cancer cell
line was established in 1951 by Dr. George Gey, Mary Kubicek, and coworkers at Johns Hopkins
University. The cells obtained from a biopsy of a cervical tumor remained viable in a nutrient solution of
chicken plasma.78,79 Although the medium and conditions for which human cells are grown has changed
over the years, the nature of cancer cells to sustain replicative ability and achieve immortality has
remained true. The experiments in the subsequent chapters of this thesis involve the use of established
GBM cell lines and SV40 transformed human astroglia cell line purchased from American Type Culture
Collection (ATCC). This chapter described the procedures used to culture and maintain these GBM cell
lines.
Material and Methods
Established Cell Line Culture: Established GBM cell lines typically grow as adherent cultures
that maintain rapid proliferative abilities and are insensitive to contact inhibition. Adherent human GBM
cell lines LN229 and T98G as well as SVG p12 human astroglial cells (ATCC) were cultured in specially
formulated Dulbecco's Modified Eagle Medium (DMEM) without glucose, L-glutamine, and sodium
pyruvate (DMEM; Corning, Manassas, VA) supplemented with 4.5 g/L D-(+)-glucose (Sigma-Aldrich,
St. Louis, MO), 0.29 g/L L-glutamine (Gibco, Madison, WI), 0.11 g/L sodium pyruvate (Gibco), and 10%
fetal bovine serum (FBS; Atlanta Biological, Atlanta, GA). Culture medium was sterile filtered using a
0.1 µm asymmetrical polyethersulfone membrane filter (ThermoFisher Scientific, Whaltham, MA). All
cells were cultured under standard conditions (37 °C and 5% CO2).
Passaging of Cell Lines: Cells were passaged when confluence reached approximately 90%.
Cells were enzymatically disassociated from the flask using Trypsin/EDTA (Gibco), cells were
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resuspended in DMEM, and centrifuged at 280 rcf for three minutes. Supernatant was removed and cell
pellet was resuspended in DMEM. Cell count was determined using trypan blue exclusion method and
cells were subsequently subcultured at the desired confluency in new flasks.

Figure 3. Morphology of adherent LN229, T98G, and SVG p12 cells. (a) Image of LN229 GBM cells. (b) Image
of T98G GBM cells. (c) Image of SVG p12 human astroglial cells. All cells were culture under standard conditions
in specialty DMEM supplemented with 4.5 g/L D-(+)-glucose, 10% FBS, 0.29 g/L L-glutamine, and 0.11 g/L
sodium pyruvate. Scale bar indicates a length of 250 µm. Images were obtained at 10X objective using EVOS
M7000 imaging system.
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CHAPTER 4: ANALYZING CYTOTOXICITY OF GLUCOSE RESTRICTED MEDIA IN
COMBINATION WITH TEMOZOLOMIDE IN GBM CELLS.

Introduction
Temozolomide (TMZ) is the standard chemotherapy agent for the treatment of GBM. Fasting
induces systemic changes such as reducing anabolic hormones and systemic glucose concentration.
Glucose restriction has been shown to augment the efficiency of chemotherapy against cancer cells while
having protective effects in normal cells. The experiments in this chapter were designed to analyze the
effects of glucose restriction in combination with temozolomide in human GBM LN229 and T98G cell
lines (ATCC) through CellTiter-Glo® 2.0 cell viability assay (Promega, Madison, WI). The data indicates
that glucose restriction does augment the efficiency of TMZ in LN229 and T98G GBM cell lines.
However, the vehicle (DMSO) used to carry the drug also proved to be cytotoxic to both GBM cell lines.
Therefore, this initial evidence suggests fasting may be a useful method to increase the efficiency of TMZ
for the treatment of GBM, but further investigation is warranted.
Methods and Materials
Preparation of Cell Culture Medium: Normal glucose media, DMEM containing 2.0 g/L D-(+)glucose (Sigma-Aldrich), 0.29 g/L L-glutamine (Gibco), 0.11 g/L sodium pyruvate (Gibco), and 10%
FBS (Atlanta Biological), was prepared as stated previously. Glucose restricted media was prepared
through a 1:3 dilution of the normal glucose media into glucose-free DMEM containing, 0.29 g/L Lglutamine (Gibco), 0.11 g/L sodium pyruvate (Gibco), and 10% FBS (Atlanta Biological). The final
concentration glucose restricted media was 0.5 g/L g/L D-(+)-glucose.
Preparation of Temozolomide: Temozolomide (TMZ) was purchased from Sigma-Aldrich (St.
Louis, MO) and dissolved into 99.7% Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich) to a concentration of
50 mM. To ensure complete solubility of TMZ in DMSO, the solution was vortexed at maximum speed.
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Serial dilution of the 50 mM TMZ stock was then performed 1:1 in DMSO to achieve the following
TMZ-DMSO concentrations: 50 mM, 25 mM, 12.500 mM, 6.250 mM, 3.125 mM, 1.562 mM, 0.781 mM,
0.391 mM, and 0.195 mM. The stock concentrations was subsequently used to create working
concentrations in glucose restricted media (DMEM, 0.5 g/L glucose, 0.29 g/L L-glutamine, 0.11 g/L
sodium pyruvate, 10% FBS) and normal media (DMEM (2.0 g/L glucose, 0.29 g/L L-glutamine, 0.11 g/L
sodium pyruvate, 10% FBS) that all contained equal amounts of DMSO (2% DMSO v/v DMEM). A
control solution of 2 % DMSO in both glucose restricted DMEM and normal DMEM was also prepared
(Figure 4B).
Cell Line Culture: Cells were cultured in DMEM as previously discussed. Briefly, cells were
detached from flasks using trypsin-EDTA, pelleted by centrifugal force, and resuspended into one mL of
DMEM. Cell count of cell suspension was subsequently done using trypan-blue exclusion method. In
order to minimize pipetting errors, appropriate amount of cell suspension was added to a conical tube
containing DMEM to achieve a final concentration of 50,000 cells/mL, seeded 5,000 cells/well (100 µL)
into 96-well tissue culture treated microplates (Corning) using a multi-channel pipettor, briefly
centrifuged at 32 rcf to expedite attachment, and incubated for 2 hours under standard conditions.
At 2 hours after plating, the original complete medium was carefully removed using a
multichannel pipettor and replaced with either glucose restricted media (DMEM, 0.5 g/L glucose, 0.29
g/L L-glutamine, 0.11 g/L sodium pyruvate, 10% FBS) or normal complete media DMEM, 2.0 g/L
glucose, 0.29 g/L L-glutamine, 0.11 g/L sodium pyruvate, 10% FBS) for 24 hours. After 24 hours, media
was removed and replaced with varying concentration of TMZ or the DMSO control using a multichannel
pipettor. The final volume of media was 100 µL per well and each treatment group was prepared in
triplicate. Plates were sustained in standard conditions. TMZ treatment lasted a total of 96 hours.

22

Cell viability assay: Following 96-hour exposure to TMZ, cytotoxicity was assessed by
luminescence using CellTiter-Glo 2.0 cell viability assay (Promega) per manufacture’s protocol. Briefly,
CellTiter-Glo 2.0 reagent was removed from -20 °C and allowed to equilibrate to room temperature (RT).
Following this, 100 µL of CellTiter-Glo 2.0 reagent was added at a 1:1 ratio of cell culture medium to
each well. Cell lysing was stimulated through agitation by placing plates on an orbital shaker for two
minutes. Luminescent signal was stabilized through a ten-minute incubation at RT in the absence of light.
Finally, luminescence was recorded using a Modulus II Microplate Reader (Turner Biosystems,
Sunnyvale, CA). CellTiter-Glo is an extremely sensitive luciferin-based assay that determines the number
of viable cells by quantifying intracellular ATP levels (Figure 5).
Statistical Analysis: Reported values indicate the mean luminescence values of three replicates
from CellTiter-Glo 2.0 assay, adjusted to the blank controls, and converted to percent viability relative to
the adjusted, average vehicle control luminescence values (equation 1). IC50 of TMZ for each cell line
was generated by plotting the average cell viability for each dose against the log function of their
respective TMZ dose (µM), fitted to a dose response curve in Prism 5 (GraphPad Software, San Diego,
CA). Significance was denoted by one asterisk (*) where p<0.05, two (**) where p<0.01, and three (***)
where p<0.001. All data presented show the standard deviation of the mean (SD).
To determine the effects of glucose restriction and DMSO on cell viability, mean luminescence
values of three replicates were converted to cell viability as previously described. The graph was
generated by potting the average cell viability under each condition fit to a group column analysis in
Prism 5 (GraphPad Software). Differences between groups was found using two-way ANOVA and
Significance was denoted by one asterisk (*) where p<0.05, two (**) where p<0.01, and three (***)
where p<0.001. All data presented show the standard deviation of the mean (SD). Post Hoc analysis using
tukey was performed to look for differences between groups (not shown).
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% 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = (

𝑅𝐿𝑈𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑅𝐿𝑈𝑎𝑣𝑔. 𝑏𝑙𝑎𝑛𝑘
) × 100%
𝑅𝐿𝑈𝑎𝑣𝑔. 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 − 𝑅𝐿𝑈𝑎𝑣𝑔. 𝑏𝑙𝑎𝑛𝑘

Equation 1. Determining cytotoxicity from CellTiter-Glo 2.0. The experimental value from each replicate
(RLUsample) was subtracted by the average blank (RLUavg. blank). This value was divided by the average vehicle value
(RLUavg. vehicle) that was also subtracted by the RLUavg. blank. Finally, the value was multiplied by one hundred to
convert it to percent viability.

Figure 4. Temozolomide (TMZ) dilution scheme. Stock 50 mM solution of TMZ in DMSO was prepared.
Subsequent 1:1 serial dilution was prepared in DMSO ranging from 50 mM-0.2 mM TMZ. Equal parts of these
dilutions were used to make the TMZ working concentrations ranging from 1000 µM to 3.9 µM in culture medium.
A vehicle control (DMSO) was also prepared.

Figure 5. CellTiter-Glo 2.0 Assay principal. Mono-oxygenation of luciferin catalyzed by Ultra-Glo Luciferase
enzyme in the presence of Mg2+, ATP and O2 to produce a stable “glow-type” luminescent.80
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Results
The effects of glucose restriction and DMSO on viability of GBM cell lines.
DMSO is an organic, aprotic solvent that is used to solubilize an abundant of pharmaceutical
compounds.81 Due to its amphipathic nature, DMSO is commonly used as the solvent of choice for drug
delivery during in vitro studies.82,83 However, cytotoxicity to DMSO has been demonstrated at relatively
low concentrations.84 Therefore, DMSO cytotoxicity was evaluated in GBM cells LN229 and T98G
incubated in both normal and glucose restricted media. Glucose restriction alone significantly inhibited
proliferation of LN229 (p <0.01) (figure 6A). Furthermore, glucose restriction significantly inhibited
growth of T98G cells (p <0.001) (figure 6B) to a greater extent compared to LN229 (figure 6A).
Regardless of glucose restriction, 2% DMSO (v/v) was found to be cytotoxic in both LN229 (p <0.001)
and T98G cells (p <0.001) (Figure 6).
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B

Figure 6. DMSO is cytotoxic to GBM cells. DMSO cytotoxicity was tested in GBM cell lines (A) LN229 and (B)
T98G. Cells were plated at 5,000 cells per well and incubated in low glucose (0.5 g/L glucose) or normal glucose
(2.0 g/L glucose) DMEM supplemented with 10% FBS, 0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24
hours. Percent viability was determined through CellTiter-Glo® 2.0 cell viability assay after 96-hour treatment with
2% DMSO (3.55 M) v/v DMEM (white). Reported values indicate the mean of three replicates converted to percent
of untreated cells cultured in 2.0 g/L glucose in Prism 5 (GraphPad Software). All data presented as mean (SD); *
p<0.05, ** p<0.01, *** p<0.001, two-way ANOVA.
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Cytotoxic effects of glucose restriction in combination with temozolomide in GBM Cell lines.
We sought to determine the effects glucose restriction on the efficiency of TMZ in both LN229
and T98G cell lines. As described earlier, cells were incubated in low glucose media (0.5 g/L) or normal
glucose (2.0 g/L) DMEM for 24 hours prior to, and during treatment with TMZ. Following 96 hours of
TMZ treatment, cell viability was assessed using the CellTiter-Glo® 2.0 cell viability assay. Regardless
of glucose concentration, both LN229 (Figure 7) and T98G (Figure 8) cells responded to increasing
concentrations of TMZ in a dose-dependent manner. The results from a 96-hour treatment with TMZ in
LN229 cells indicate that glucose restriction augments the efficiency of TMZ (Figure 7). Under normal
glucose media, a dose of 632.2 µM was necessary to cause 50% cell death (IC50) in LN229 cells (Table
1). Under glucose restricted media, the IC50 value of TMZ decreased to 429.5 µM in LN229 cells.
Similar results were obtained following 96 hours treatment of TMZ in T98G cells (Figure 8). The IC50
value decreased from 469.2 µM to 301.4 µM when T98G cells were cultured in glucose restricted media.
There were no outliers found in either T98G or LN229 cytotoxicity assays.
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Figure 7. Glucose restriction sensitizes LN229 GBM cells to temozolomide treatment. GBM cell line LN229
were tested for glucose restriction induced sensitization to TMZ. Cells were plated at 5,000 cells per well and
incubated in low glucose (Red, 0.5 g/L glucose) or normal glucose (Black, 2.0 g/L glucose) DMEM supplemented
with 10% FBS, 0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24 hours. Percent viability was determined
through CellTiter-Glo® 2.0 cell viability assay after 96-hour treatment with 0-1000 µM TMZ. Reported values
indicate the mean of three replicates converted to percent of vehicle control (DMSO) group in Prism software. All
data presented as mean (SD).
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Figure 8. Glucose restriction sensitizes T98G GBM cells to temozolomide treatment. GBM cell line T98G were
tested for glucose restriction induced sensitization to TMZ. Cells were plated at 5,000 cells per well and incubated in
low glucose (Red, 0.5 g/L glucose) or normal glucose (Black, 2.0 g/L glucose) DMEM supplemented with 10%
FBS, 0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24 hours. Percent viability was determined through
CellTiter-Glo® 2.0 cell viability assay after 96-hour treatment with 0-1000 µM TMZ. Reported values indicate the
mean of three replicates converted to percent of vehicle control (DMSO) group in Prism software. All data presented
as mean (SD).
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Chapter 4. Effects of glucose restricted media in combination with TMZ (DMSO vehicle)
IC50 value of temozolomide (µM)
Cell line
LN229 (GBM)

0.5 g/L glucose
429.5

2.0 g/L glucose
638.2

P Value
<0.001 (***)

T98G (GBM)

301.4

469.2

0.026 (*)

Chapter 5. Effects of glucose restricted media in combination with TMZ
IC50 value of temozolomide (µM)
Cell line
LN229 (GBM)
T98G (GBM)
SVG p12 Astroglial)

0.5 g/L glucose
85.29
371.4
92.80

2.0 g/L glucose
273.5
678.3
77.19

P Value
<0.001 (***)
0.005 (**)
0.125 (NS)

Chapter 6. Effects of ß-HB in combination with TMZ
IC50 value of temozolomide (µM)

LN229 (GBM)
T98G (GBM)
SVG p12 (Astroglial)

0.5 g/L glucose +
2.0 mM ß-HB
76.66
177.1
246.1

Cell line

0.5 g/L glucose

LN229 (GBM)
T98G (GBM)
SVG p12 (Astroglial)

85.29
371.4
92.80

Cell line

2.0 g/L glucose

LN229 (GBM)
T98G (GBM)
SVG p12 (Astroglial)

273.5
678.3
77.19

Cell line

2.0 g/L glucose +
2.0 mM ß-HB
189.1
442.3
187.8
0.5 g/L glucose +
2.0 mM ß-HB
76.66
177.1
246.1
2.0 g/L glucose +
2.0 mM ß-HB
189.1
442.3
187.8

P Value
<0.001 (***)
<0.001 (***)
<0.001 (***)

P Value
0.508 (NS)
<0.001 (***)
<0.001 (***)

P Value
0.024 (*)
0.004 (**)
<0.001 (***)

Table 1. Summary of Temozolomide half maximal inhibitory concentration (IC50) value in GBM and normal
astrocyte cells. Cells were cultured in low glucose (0.5 g/L glucose) or normal glucose (2.0 g/L glucose), with or
without ß-HB, DMEM supplemented with 10% FBS, 0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24
hours. Percent viability was determined through CellTiter-Glo® 2.0 and CellQuanti-Blue™ Cell Viability Assay
after 96-hour treatment with 0-1000 µM and 0-1500 µM TMZ, respictively. IC50 of TMZ for each cell line was
generated by plotting the average cell viability for each dose relative to their control group against the log function
of their respective TMZ dose (µM), fitted to a dose response curve in Prism 5 (GraphPad Software). Summary of
IC50 value is shown with respect to the chapter in which they appear.
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Discussion
Glucose restriction enhanced the efficiency of TMZ to different extents in both GBM cell lines
(LN229 and T98G) (Figure 7 and 8). Glucose restriction sensitized both LN229 and T98 cell lines to
TMZ treatment (Figure 7 and 8). In LN229, the IC50 value decreased from 638.2 µM (Table 1) to 429.5
µM, a 32.7 % decrease, when cultured under glucose restricted media (p <0.001) (Table 1). In T98G cells,
the IC50 value decreased from 469.2 µM to 301.4 µM, a 35.8% decrease, when cultured under glucose
restricted media (p <0.001) (Table 1). So, at first glance, it appears the hypothesis that glucose restriction
prior to, and during TMZ treatment would further sensitize GBM cells to TMZ is supported.
When comparing the IC50 values of LN229 and T98G under both normal and glucose restricted
media, this data suggests that T98G cells are more sensitive to TMZ than LN229 cells. This data is
surprising based on published MGMT status of these two cell lines. As discussed earlier (Chapter 2),
MGMT’s primary function is the removal of the TMZ induced, cytotoxic O6MeG residues of DNA. It has
been shown that MGMT expression is directly correlated to TMZ resistance. In general, methylation
located at the gene promoter acts to repress the expression of said gene. LN229 and T98G cells were
chosen for these experiments because of their published differences in MGMT promoter status. The
literature suggests that LN229 cells are hyper-methylated at the MGMT promoter region, do not express
MGMT, and are thus TMZ-sensitive.85 T98G cells have an unmethylated MGMT promoter, express
MGMT and are TMZ resistant.86 In the data we obtained, IC50 values under glucose restricted media
were 429.5 µM in LN229 cells and 301.4 µM in T98G cells. Under normal glucose media, the IC50 were
638.2 µM in LN229 cells and 469.2 µM in T98G cells. The higher IC50 values obtained for LN229
compared to T98G cells suggest LN229 cells are more resistant to TMZ than T98G cells, which
contradicts the literature. It may be possible the cell lines were switched during analysis using the
microplate reader. This could be determined by performing short tandem repeat analysis to confirm the
identity of the cell lines used. It may also be possible that the vehicle control (DMSO) may have
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differentially affected the two cell lines. Consequently, the cytotoxicity of both cell lines to the drug
vehicle was evaluated.
Granular TMZ was solubilized into liquid with the use of DMSO as a vehicle carrier. The
maximum solubility of TMZ in pure DMSO (14.1 M) is 10 mg/mL (50 mM). At this concentration, the
amount of DMSO necessary to achieve the highest working concentration of TMZ is 2% DMSO (v/v).
The cytotoxic effect of DMSO at a concentration of 2% v/v, as well as glucose restriction, was evaluated
in both LN229 and T98G cell lines (Figure 6). As expected, glucose restriction significantly inhibited
growth of both LN229 (figure 6A) and T98G cells (figure 6B). However, regardless of glucose restriction
DMSO induced significant cytotoxicity of both LN229 (figure 6A) and T98G cells (figure 6B). Since
DMSO was held constant at 2% v/v during the TMZ dose-dependent experiments, we can attribute the
differences in viability cultured under glucose restricted media to changes in TMZ sensitivity within each
cell line. However, the results from the subsequent chapter of this thesis, to determine the effects of
glucose restriction with TMZ by dissolving TMZ straight into culture medium, indicates that LN229 and
T98G cells were affected differently by the DMSO.
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CHAPTER 5: ANALYZING CYTOTOXICITY OF GLUCOSE RESTRICTED MEDIA IN
COMBINATION WITH TEMOZOLOMIDE ADMINISTERED WITHOUT DMSO IN GBM AND
HUMAN ASTROGLIAL CELLS.
Introduction
Temozolomide (TMZ) is the standard chemotherapy agent for the treatment of GBM. Fasting
induces systemic changes such as reducing anabolic hormones and systemic glucose concentration.
Glucose restriction has been shown to augment the efficiency of chemotherapy against cancer cells while
having protective effects in normal cells. The previous chapter evaluated the effects of glucose restriction
in combination with TMZ on GBM cell lines LN229 and T98G. However, the organic solvent dimethyl
sulfoxide (DMSO) utilized as a vehicle proved itself to be significantly cytotoxic to both LN229 and
T98G cell lines. This initial evidence suggesting glucose restriction can augment the efficiency of TMZ
against GBM cells remains somewhat unclear.
The hydrophobic side chains of TMZ make it only mildly soluble in water. Nonetheless, TMZ is
soluble in water up to a concentration of 0.31 mg/mL (1.6 mM).87 The experiments in this chapter were
designed to analyze the effects of glucose restriction in combination with TMZ in human GBM cell lines,
LN229 (ATCC) and T98G (ATCC), as well as a human astroglial cell line, SVG p12 without the
confounding factor of DMSO as a vehicle. The data indicates that glucose restriction does augment the
efficiency of TMZ in LN229 and T98G GBM cell lines. Furthermore, glucose restriction did not affect
the efficiency of TMZ in SVG p12 astroglial cell line. Therefore, this initial evidence suggests fasting
may be a useful method to increase the efficiency of TMZ for the treatment of GBM.
Materials and Methods
Preparation of Cell Culture Medium: Normal glucose media, DMEM containing 2.0 g/L D-(+)glucose (Sigma-Aldrich), 0.29 g/L L-glutamine (Gibco), 0.11 g/L sodium pyruvate (Gibco), and 10%
FBS (Atlanta Biological), was prepared as stated previously. Glucose restricted media was prepared
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through a 1:3 dilution of the normal glucose media into glucose-free DMEM containing 0.29 g/L Lglutamine (Gibco), 0.11 g/L sodium pyruvate (Gibco), and 10% FBS (Atlanta Biological). The final
concentration glucose restricted media was 0.5 g/L g/L D-(+)-glucose.
Preparation of Temozolomide: Temozolomide (TMZ) was purchased from Sigma-Aldrich (St.
Louis, MO) and dissolved into glucose restricted media (DMEM, 0.5 g/L glucose, 0.29 g/L L-glutamine,
0.11 g/L sodium pyruvate, 10% FBS) and normal media (DMEM, 2.0 g/L glucose, 0.29 g/L L-glutamine,
0.11 g/L sodium pyruvate, 10% FBS) to a concentration of 1500 µM. To ensure complete solubility of
TMZ in DMEM, the solution was vortexed at maximum speed. Serial dilution of the 1.5 mM TMZ stock
was then performed 1:1 in media to achieve the following working concentrations: 1500 µM, 750 µM,
375 mM, 187.5 mM, 93.75 µM, 46.88 µM, 23.44 µM, 11.72 µM, and 5.86 µM A control solution for
both glucose restricted DMEM and normal DMEM was also prepared (figure 11).
Cell Line Culture: Cells were cultured in DMEM as previously discussed. Briefly, cells were
detached from flasks using trypsin-EDTA, pelleted by centrifugal force, and resuspended into one mL of
DMEM. Cell count of cell suspension was subsequently done using trypan-blue exclusion method. In
order to minimize pipetting errors, appropriate amount of cell suspension was added to a conical tube
containing DMEM to achieve a final concentration of 50,000 cells/mL, seeded 5,000 cells/well (100 µL)
into 96-well tissue culture treated microplates (Corning) using a multi-channel pipettor, briefly
centrifuged at 32 rcf to expedite attachment, and incubated for 2 hours under standard conditions.
At 2 hours after plating, the original complete medium was carefully removed using a
multichannel pipettor and replaced with either glucose restricted media (DMEM, 0.5 g/L glucose, 0.29
g/L L-glutamine, 0.11 g/L sodium pyruvate, 10% FBS) or normal complete media DMEM, 2.0 g/L
glucose, 0.29 g/L L-glutamine, 0.11 g/L sodium pyruvate, 10% FBS) for 24 hours. After 24 hours, media
was removed and replaced with varying concentration of TMZ or control (media only) using a
multichannel pipettor. The final volume of treatment media was 100 µL per well and each treatment
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group was prepared in triplicate. Plates were sustained in standard incubation conditions. TMZ treatment
lasted a total of 96 hours.
Cell viability assay: Following 96-hour exposure to TMZ, cytotoxicity was assessed by
florescence using CellQuanti-Blue™ cell viability assay kit (BioAssay Systems, Hayward, CA) per
manufacture’s protocol. Briefly, CellQuanti-Blue™ reagent was removed from 4 °C and allowed to
equilibrate to RT. Media was carefully removed using a multichannel pipettor and replaced was 100 µL
of DMEM-phenol red free media (corning) supplemented with 10% FBS. Following this, 10 µL of
CellQuanti-Blue™ reagent was added to each well. Cells were briefly centrifuged at 32 rcf to homogenize
CellQuanti-Blue™ reagent in the culture medium and incubated for 2 hours under standard conditions.
After two hours, measurement of CellQuanti-Blue™ reagent fluorescence intensity was measured
(excitation wavelength = 525 nm, emission wavelength = 590 - 620 nm) using a Modulus II Microplate
Reader (Turner Biosystems, Sunnyvale, CA). CellQuanti-Blue™ is a sensitive assay that utilizes
resazurin-based compound (non-fluorescent) that upon reduction by metabolically active cells is
converted into a resorufin (highly fluorescent). Viable cells can readily reduce resazurin, while non-viable
(metabolically inactive) cells cannot. CellQuanti-Blue™ thus determines the number of viable cells by
quantifying fluorescent intensity, which is directly proportional to the number of viable cells (Figure 12).
Statistical Analysis: Reported values indicate the mean fluorescence values of three replicates
from CellQuanti-Blue™ assay, adjusted to the blank controls, and converted to percent viability relative
to the adjusted, average vehicle control fluorescence values (equation 2). IC50 of TMZ for each cell line
was generated by plotting the average cell viability for each dose against the log function of their
respective TMZ dose (µM), fitted to a dose response curve in Prism 5 (GraphPad Software, San Diego,
CA). Significance was denoted by one asterisk (*) where p<0.05, two (**) where p<0.01, and three (***)
where p<0.001. All data presented show the standard deviation of the mean (SD).
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% 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = (

𝑅𝐹𝑈𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑅𝐹𝑈𝑎𝑣𝑔. 𝑏𝑙𝑎𝑛𝑘
) × 100%
𝑅𝐹𝑈𝑎𝑣𝑔. 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 − 𝑅𝐹𝑈𝑎𝑣𝑔. 𝑏𝑙𝑎𝑛𝑘

Equation 2. Determining cytotoxicity from CellQuanti-Blue™. The experimental value from each replicate
(RFUsample) was subtracted by the average blank (RFUavg. blank). This value was divided by the average vehicle value
(RFUavg. vehicle) that was also subtracted by the RFUavg. blank. Finally, the value was multiplied by one hundred to
convert it to percent viability.

Figure 9. Temozolomide (TMZ) dilution scheme. Stock 1500 µM solution of TMZ in culture medium was
prepared. Subsequent 1:1 serial dilution was used to make the TMZ working concentrations ranging from 1500 µM
to 5.86 µM in culture medium. A vehicle control (Media only) was also prepared.

Figure 10. CellQuanti-Blue™ Assay principal. Chemical structures of resazurin and resorufin. Reductases of
metabolically active, viable cells reduce non-fluorescent resazurin in the presence of NADH into the highly
fluorescent product resorufin.
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Results
Cytotoxic effects of glucose restriction in combination with temozolomide in GBM Cell lines
We sought to determine the effects of glucose restriction on the efficiency of TMZ in LN229 and
T98G GBM cell lines. As described earlier, cells were incubated in low glucose media (0.5 g/L) or
normal glucose (2.0 g/L) DMEM for 24 hours prior to, and during treatment with TMZ. Following 96
hours of TMZ treatment, cell viability was assessed using the of CellQuanti-Blue™ cell viability assay.
The results from a 96-hour treatment with TMZ in LN229 cells indicate that glucose restriction augments
the efficiency of TMZ (Figure 11). When cultured in normal glucose media and treated with TMZ, the
IC50 value was 273.5 µM in LN229 cells. When cultured in restricted glucose conditions, the IC50 value
of TMZ decreased to 85.3 µM in LN229 cells (p <0.001) (Table 1). T98G cells responded in a similar
fashion following a 96-hour treatment with TMZ, with glucose restriction augmenting the efficiency of
TMZ (Figure 12). The IC50 value decreased from 678.4 µM to 371.4 µM when T98G cells were cultured
in restricted glucose conditions (p =0.005) (Table 1).
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Figure 11. Glucose restriction sensitizes LN229 GBM cells to temozolomide treatment. GBM cell line LN229
were tested for TMZ sensitivity under glucose restricted media. LN229 cells were plated at 5,000 cells per well and
incubated in low glucose DMEM (Red, 0.5 g/L glucose) or in normal glucose DMEM (Black, 2.0 g/L glucose) for
24 hours. Percent viability was determined through CellQuanti-Blue™ cell viability assay after 96-hour treatment
with 0-1500 µM TMZ. Reported values indicate the mean of three replicates converted to percent of control (media
only) in Prism software. Reported values presented as dose-response curve using Prism software.
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Figure 12. Glucose restriction sensitizes T98G GBM cells to temozolomide treatment. GBM cell line T98G
were tested for TMZ sensitivity under glucose restricted media. T98G cells were plated at 5,000 cells per well and
incubated in low glucose DMEM (Red, 0.5 g/L glucose) or in normal glucose DMEM (Black, 2.0 g/L glucose) for
24 hours. Percent viability was determined through CellQuanti-Blue™ cell viability assay after 96-hour treatment
with 0-1500 µM TMZ. Reported values indicate the mean of three replicates converted to percent of control (media
only) in Prism software. Reported values presented as dose-response curve using Prism software.
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Cytotoxic effects of glucose restriction in combination with temozolomide in human astroglial cell line
In contrast to GBM cell lines, glucose restriction decreased the cytotoxicity of TMZ in SVG p12
cells. The IC50 value slightly increased from 77.2 µM to 92.8 µM when SVG p12 cells were cultured in
restricted glucose conditions (Table 1). This slight decrease in IC50 suggests a protective effect when
SVG p12 cells were cultured in glucose restricted media, however the change in IC50 was found to be not
significant (NS) (p =0.125) (Table 1).

SVGp12

100

Viability %

75
50
25

0.5 g/L glucose
2.0 g/L glucose

0
0

1

2

3

Log[Temozolomide]
Figure 13. Glucose restriction has no effect on SVG p12 normal astrocyte sensitivity to temozolomide
treatment. Normal human astrocyte cell line SVG p12 were tested for TMZ sensitivity under glucose restricted
media. Cells were plated at 5,000 cells per well and incubated in low glucose (Red, 0.5 g/L glucose) or normal
glucose (Black, 2.0 g/L glucose) DMEM supplemented with 10% FBS, 0.29 g/L L-glutamine, and 0.11 g/L sodium
pyruvate for 24 hours. Percent viability was determined through CellQuanti-Blue™ cell viability assay after 96-hour
treatment with 0-1500 µM TMZ. Reported values indicate the mean of three replicates converted to percent of
control (media only) in Prism software. Reported values presented as dose-response curve using Prism software.
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Discussion
Glucose restriction enhanced the efficiency of TMZ in both GBM cell lines, LN229 and T98G. In
LN229, the IC50 value decreased from 273.5 µM to 85.29 µM, a 68.8% decrease, when cultured under
glucose restricted media (p <0.001) (Table 1) (Figure 11). In T98G cells, the IC50 value decreased from
678.3 µM to 371.4 µM, a 45.3% decrease, when cultured under glucose restricted media (p <0.01) (Table
1) (Figure 12). These changes in IC50 values suggest that glucose restriction augments the cytotoxic
effects of TMZ in GBM cell lines. Furthermore, the observed IC50 values were larger in T98G compared
to LN229 cells under both glucose restricted media and normal glucose media. Thus, our data suggest that
T98G cells are inherently more resistant to TMZ than LN229 cells, a notion that is supported by the
literature.
In contrast to GBM cells, glucose restriction slightly reduced the efficiency of TMZ in normal
human astroglial cell line SVG p12. In SVG p12 cells, glucose restriction increased the IC50 value of
TMZ from 77.19 µM to 92.80 µM, a 20.2% increase (NS) (Table 1) (Figure 13). However, this change in
IC50 value was found to be not significant. Although glucose restriction with TMZ showed no significant
effect in SVG p12, glucose restriction did potentiate TMZ cell death in both of GBM cell lines tested.
This observation seems to indicate that glucose restriction differentially effects normal and cancer cells by
selectively augmenting the cytotoxic effects of TMZ in GBM cells. Thus, these results support the
potential use of fasting in combination with TMZ for the treatment of GBM.
One hypothesis by which fasting enhances TMZ in LN229 cells is through the modulation of
nutrient sensing pathways that governs cell behavior. In a fed state, anabolic signaling promotes cell
growth/replication largely through the phosphoinositide 3-kinase (PI3K) pathway and mTORC1. Insulin
and IGF-1 activation of PI3K/Akt/mTORC1 pathway leads to increased uptake of glucose and amino
acids, activation of glycolytic enzymes phosphofructokinase and hexokinase, increased protein
translation, increased lipid synthesis, increased nucleotide synthesis, and cell growth.88 In addition to
activation of PI3K/Akt/mTORC1 pathway, the inactivation of AMP-activated protein kinase (AMPk)
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occurs. AMPk is a protein complex whose activity is controlled by intracellular ATP/AMP levels. In a fed
state, when ATP/AMP levels are high and ATP is bound to the regulatory subunit of AMPk, AMPk is
inactive. In a fasted state, when ATP/AMP levels are low and AMP is bound to the regulatory subunit of
AMPk, AMPk is active.89,90 Active AMPk promotes cell survival/repair/maintenance by inhibiting
mTORC1 and activating p53.91 p53 is one of the most studied tumor suppressor genes whose activation
by cellular stress induces many different antiproliferative signals, such as cell cycle arrest, apoptosis, and
DNA repair. Activation of p53 leads to activation of phosphatase and tensin homolog (PTEN), a tumor
suppressor gene that inactivates Akt.92,93 This inverse relationship between AMPk/p53/PTEN and
PI3K/Akt/mTORC1 is essential for maintaining cellular homeostasis throughout a range of nutrient
conditions (Figure 14A). Cancer cells have oncogenic mutations that govern self-sufficient growth and
altered metabolism. A comprehensive genomic characterization of GBM found mutations to at least one
genetic event in the PI3k pathway in 86% of the 206 GBM samples.94 Mutations in the
PI3k/mTORC1/Akt pathway help to sustain proliferative signals even when nutrient availability is
inadequate for growth and division. T98G have a mutation in PTEN, while LN229 cells have mutation in
p53.95,96 These mutation hinders the ability of T98G and LN229 to maintain homeostasis in a fasting state,
making them more susceptible to TMZ (Figure 14B). Therefore, future studies evaluating the relative
expression and activity of PI3K/Akt/mTORC1 pathway and the AMPk/p53/PTEN pathway in response to
fasting conditions is warranted to further understand the DSR between normal brain and GBM cells.
As discussed previously, depletion of glucose is only one of many systemic alterations that occur
during fasting. Therefore, simply restricting the concentration of glucose within culture medium does not
accurately reflect the response fasting with TMZ may have in patients. To account for an additional
fasting induced adaptation, the next chapter of this thesis investigates the effects of ketone bodies in
combination with TMZ on GBM and normal astroglial cell lines.
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Figure 14. Differential stress response (DSR) between normal cells and LN229 cells in response to fasting
conditions. (A) In a fed state (left), normal cells respond to high nutrient availability and Insulin/IGF-1 signaling
through the activation of PI3K/Akt pathway. Activation of the PI3K/Akt pathways leads increases glucose
metabolism and mTORC1 activation to increase protein, nucleotide, and lipid synthesis. High glycolytic flux
increases intracellular ATP/AMP ratio, inhibiting AMPk activity. In a fasted state (right), low nutrient availability
leads to a drop in ATP/AMP concentrations and the subsequent activation of AMPk. AMPk directly inhibits
mTORC1, and activates p53 and PTEN to inhibit PI3k/Akt signaling. This inverse relationship in response relative
nutrient availability allows normal cells to maintain homeostasis. (B) LN229 cells have mutation in p53 and T98G
cells have a mutation in PTEN that impairs their ability to respond to fasting conditions. In a fed state (left), high
nutrient availability and insulin/IGF-2 signaling activates PI3K/Akt/mTORC1 pathway to promote cell
growth/division. In a fasted state (right), mutant p53 and PTEN inhibit LN229 and T98G ability to respond to
fasting signals and continue to promote growth/division, making them more susceptible to TMZ. Active pathways
are shown in black, inactive pathways are shown in red, and mutated pathways are shown in green. Image was
drawn using Adobe Illustrator 2020.
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CHAPTER 6: ANALYZING CYTOTOXICITY OF GLUCOSE RESTRICTED MEDIA
SUPPLEMENTED WITH β-HYDROXYBUTYRATE IN COMBINATION TEMOZOLOMIDE IN
GBM AND HUMAN ASTROGLIAL CELLS.
Introduction
Temozolomide (TMZ) is the standard chemotherapy agent for the treatment of GBM. During
fasting, the reduction of blood glucose induces a variety of systemic changes to occur. Catabolic
hormones signal the mobilization of fatty acids from adipose tissue. In the liver, fatty acids are broken
down into acetyl-CoA which serves as the starting material in the synthesis of ketone bodies (KB). KB
are hepatically produced and systemically released molecules that serve as an energy source for the heart,
skeletal muscle, kidney, and brain.31–35 During fasting, serum concentrations of the KB ß-hydroxybutyrate
(ß-HB) can reach levels of 2 mM, and upwards of 6-8 mM during prolonged starvation.34 ß-HB readily
crosses the blood brain barrier where it is oxidized by cells of the CNS into acetyl-CoA to serve as an
energy source in the citric acid cycle.
In addition to its role as an energy substrate, β-HB has been previously to have inhibitory effects
on histone deacetylase 1 (HDAC-1).37–39 This in turn augments the efficiency of TMZ in a TMZ-resistant
GBM cell line.41 The experiments in this chapter were designed to analyze the effects ß-HB in
combination with temozolomide on the viability of two human GBM cell lines, LN229 and T98G, and a
normal human astroglial cell line, SVG p12. The data indicates that ß-HB potentiated cytotoxicity of
TMZ in LN229 cells under normal glucose media but had no effect under glucose restricted media. In
T98G cells, ß-HB potentiated cytotoxicity of TMZ under both normal glucose media and restricted
glucose conditions. In contrast to GBM cells, ß-HB reduced the cytotoxicity of TMZ in SVG p12 normal
astroglial cells under both normal glucose media restricted glucose conditions. Therefore, this initial
evidence suggests fasting may be a useful method to selectively increase cytotoxicity of TMZ in GBM
cells, while protecting normal cells.
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Materials and Methods
Preparation of Cell Culture Medium: Normal glucose media, DMEM containing 2.0 g/L D-(+)glucose (Sigma-Aldrich), 0.29 g/L L-glutamine (Gibco), 0.11 g/L sodium pyruvate (Gibco), and 10%
FBS (Atlanta Biological), was prepared as stated previously. Glucose restricted media was prepared
through a 1:3 dilution of the normal glucose media into glucose-free DMEM containing 0.29 g/L Lglutamine (Gibco), 0.11 g/L sodium pyruvate (Gibco), and 10% FBS (Atlanta Biological). The final
concentration glucose restricted media was 0.5 g/L g/L D-(+)-glucose. Sodium ß-HB (Millipore Sigma)
was dissolved into normal glucose media and glucose restricted media to a concentration of 2.0 mM.
Preparation of Temozolomide: Temozolomide (TMZ) was purchased from Sigma-Aldrich (St.
Louis, MO) and dissolved into glucose restricted media plus ß-HB and normal glucose media plus ß-HB
to a concentration of 1500 µM. To ensure complete solubility of TMZ in DMEM, the solution was
vortexed at maximum speed. Serial dilution of the 1.5 mM TMZ stock was then performed 1:1 in media
to achieve working concentrations of 1500 µM, 750 µM, 375 mM, 187.5 mM, 93.75 µM, 46.88 µM,
23.44 µM, 11.72 µM, and 5.86 µM. A control solution of glucose restricted media plus ß-HB and normal
glucose media plus ß-HB was also prepared.
Cell Line Culture: Cells were cultured in DMEM as previously discussed. Briefly, cells were
detached from flasks using trypsin-EDTA, pelleted by centrifugal force, and resuspended into one mL of
DMEM. Cell count of cell suspension was subsequently done using trypan-blue exclusion method. In
order to minimize pipetting errors, appropriate amount of cell suspension was added to a conical tube
containing DMEM to achieve a final concentration of 50,000 cells/mL, seeded 5,000 cells/well (100 µL)
into 96-well tissue culture treated microplates (Corning) using a multi-channel pipettor, briefly
centrifuged at 32 rcf to expedite attachment, and incubated for 2 hours under standard conditions.
At 2 hours after plating, the original complete medium was carefully removed using a
multichannel pipettor and replaced with either glucose restricted media plus 2.0 mM ß-HB, or normal
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glucose media plus 2.0 mM ß-HB for 24 hours. After 24 hours, media was removed and replaced with
varying concentration of TMZ or control (media only) using a multichannel pipettor. The final volume of
treatment media was 100 µL per well and each treatment group was prepared in triplicate. Plates were
sustained in standard incubation conditions. TMZ treatment lasted a total of 96 hours.
Cell viability assay: Following 96-hour exposure to TMZ, cytotoxicity was assessed by
luminescence using CellQuanti-Blue™ cell viability assay kit (BioAssay Systems) per manufacture’s
protocol. Briefly, CellQuanti-Blue™ reagent was removed from 4 °C and allowed to equilibrate to RT.
Media was carefully removed using a multichannel pipettor and replaced was 100 µL of DMEM-phenol
red free media (corning) supplemented with 10% FBS. Following this, 10 µL of CellQuanti-Blue™
reagent was added to each well. Cells were briefly centrifuged at 32 rcf to homogenize CellQuanti-Blue™
reagent in the culture medium and incubated for 2 hours under standard conditions. After two hours,
measurement of CellQuanti-Blue™ reagent fluorescence intensity (excitation wavelength = 525 nm,
emission wavelength = 590 - 620 nm) using a Modulus II Microplate Reader (Turner Biosystems,
Sunnyvale, CA). CellQuanti-Blue™ is a sensitive assay that utilizes resazurin-based compound (not
fluorescent) that upon reduction by metabolically active cells is converted into a resorufin (highly
fluorescent). Viable cells can readily reduce resazurin, while non-viable (metabolically inactive) cells
cannot. CellQuanti-Blue™ thus determines the number of viable cells by quantifying fluorescent
intensity, which is directly proportional to the number of viable cells (Figure 12).
Statistical Analysis: Reported values indicate the mean fluorescence values of three replicates
from CellQuanti-Blue™ assay, adjusted to the blank controls, and converted to percent viability relative
to the adjusted, average vehicle control fluorescence values. IC50 of TMZ for each cell line was
generated by plotting the average cell viability for each dose against the log function of their respective
TMZ dose (µM) fitted to a dose response curve in Prism 5 (GraphPad Software, San Diego, CA).
Significance was denoted to one asterisk (*) if p<0.05, two (**) if p<0.01, and three (***) if p<0.001. All
data presented show the standard deviation of the mean (SD).
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Additional analysis was done to compare the average cell viability of each cell line when cultured
in glucose restricted media verses glucose restricted media supplemented with ß-HB. In order to do so,
the data from the chapter 5, cell viability under glucose restriction and normal glucose media, were
compared to the average cell viability under glucose restricted plus ß-HB and normal glucose plus ß-HB,
respectively dose response curve in Prism 5 (GraphPad Software). Significance was denoted to one
asterisk (*) where p<0.05, two (**) where p<0.01, and three (***) where p<0.001, and all data presented
show the standard deviation of the mean (SD)
Results
Effects of glucose restriction conditions plus ß-HB in combination with temozolomide in GBM cell lines
We sought to determine the effects glucose restricted media plus ß-HB on the efficiency of TMZ
in LN229 GBM cell line. As described earlier, cells were incubated in glucose restricted media plus ß-HB
(0.5 g/L + 2.0 mM ß-HB) or normal glucose media plus ß-HB (2.0 g/L+ 2.0 mM ß-HB) DMEM for 24
hours prior to, and during treatment with TMZ. Following 96 hours of TMZ treatment, cell viability was
assessed using the of CellQuanti-Blue™ cell viability assay. The results from a 96-hour treatment with
TMZ in LN229 cells indicate that glucose restricted media plus ß-HB augments the efficiency of TMZ
(Figure 15). The IC50 value of TMZ decreased from 189.1 µM to 76.7 µM when LN229 cells were
cultured in restricted glucose media plus ß-HB (p <0.001) (Table 1) (Figure 15). Using the data from the
previous chapter, we compared the effects of TMZ under glucose restriction conditions (chapter 5) to the
effects of TMZ under glucose restriction plus ß-HB, and the effects of TMZ under normal glucose media
to the effects of TMZ under normal glucose plus ß-HB in LN229 cells. The IC50 value of TMZ decreased
from 85.29 µM to 76.66 µM when LN229 were cultured under glucose restriction plus ß-HB (NS) (Table
1) (Figure 16). The IC50 value of TMZ decreased from 273.5µM to 189.1 µM when LN229 were
cultured under normal glucose media plus ß-HB (p = 0.0243) (Table 1) (Figure 17).
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T98G cells responded in a similar fashion following a 96-hour treatment with TMZ, with glucose
restriction plus ß-HB augmenting the cytotoxicity of TMZ (Figure 16). The IC50 value decreased from
442.3 µM to 177.1 µM (p <0.001) when T98G cells were cultured in restricted glucose conditions plus ßHB (p <0.001) (Table 1) (Figure 18). Using the data from the previous chapter, we again compared the
effects of TMZ under glucose restriction conditions and normal glucose media, to their respective
counterparts containing ß-HB in T98G cells. The IC50 value of TMZ decreased from 371.4 µM to 177.1
µM when T98G were cultured under glucose restriction plus ß-HB (p <0.001) (Table 1) (Figure 19). The
IC50 value of TMZ decreased from 678.3 µM to 442.3 µM when T98G were cultured under normal
glucose media plus ß-HB (p <0.01) (Table 1) (Figure 20).
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Figure 15. Glucose restricted media supplemented with ß-HB further sensitizes LN229 cells to temozolomide.
Human GBM cell line LN229 were tested for TMZ sensitivity under glucose restricted media supplemented with ßHB. Cells were plated at 5,000 cells per well and incubated in glucose restricted media plus ß-HB (Red, 0.5 g/L
glucose + 2.0 mM ß-HB) or normal glucose media plus ß-HB (Black, 2.0 g/L glucose + 2.0 mM ß-HB) DMEM
supplemented with 10% FBS, 0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24 hours. Percent viability
was determined through CellQuanti-Blue™ cell viability assay after 96-hour treatment with 0-1500 µM TMZ.
Reported values indicate the mean of three replicates converted to percent of control (media only) in Prism software.
Reported values presented as dose-response curve using Prism software.
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Figure 16. ß-HB supplementation does not further sensitize LN229 cells cultured under glucose restricted
media to temozolomide. Human GBM cell line LN229 were tested for TMZ sensitivity under glucose restricted
media plus ß-HB. Cells were plated at 5,000 cells per well and incubated in glucose restricted media (Black, 0.5 g/L
glucose) or glucose restricted media plus ß-HB (Red, 0.5 g/L glucose + 2.0 mM ß-HB) DMEM supplemented with
10% FBS, 0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24 hours. Percent viability was determined
through CellQuanti-Blue™ cell viability assay after 96-hour treatment with 0-1500 µM TMZ. Reported values
indicate the mean of three replicates converted to percent of control (media only) in Prism software. Reported values
presented as dose-response curve using Prism software.
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Figure 17. ß-HB supplementation further sensitizes LN229 cells cultured under normal glucose media to high
doses of temozolomide. Human GBM cell line LN229 were tested for TMZ sensitivity under normal glucose media
plus ß-HB. Cells were plated at 5,000 cells per well and incubated in normal glucose media (Black, 2.0 g/L glucose)
or normal glucose media plus ß-HB (Red, 2.0 g/L glucose + 2.0 mM ß-HB) DMEM supplemented with 10% FBS,
0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24 hours. Percent viability was determined through
CellQuanti-Blue™ cell viability assay after 96-hour treatment with 0-1500 µM TMZ. Reported values indicate the
mean of three replicates converted to percent of control (media only) in Prism software. Reported values presented
as dose-response curve using Prism software.
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Figure 18. Glucose restricted media supplemented with ß-HB further sensitizes T98G cells to temozolomide.
Human GBM cell line T98G were tested for TMZ sensitivity under glucose restricted media supplemented with ßHB. Cells were plated at 5,000 cells per well and incubated in glucose restricted media plus ß-HB (Red, 0.5 g/L
glucose + 2.0 mM ß-HB) or normal glucose media plus ß-HB (Black, 2.0 g/L glucose + 2.0 mM ß-HB) DMEM
supplemented with 10% FBS, 0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24 hours. Percent viability
was determined through CellQuanti-Blue™ cell viability assay after 96-hour treatment with 0-1500 µM TMZ.
Reported values indicate the mean of three replicates converted to percent of control (media only) in Prism software.
Reported values presented as dose-response curve using Prism software.
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Figure 19. ß-HB supplementation further sensitizes T98G cells cultured under glucose restricted media to
temozolomide. Human GBM cell line T98G were tested for TMZ sensitivity under glucose restricted media plus ßHB. Cells were plated at 5,000 cells per well and incubated in glucose restricted media (Black, 0.5 g/L glucose) or
glucose restricted media plus ß-HB (Red, 0.5 g/L glucose + 2.0 mM ß-HB) DMEM supplemented with 10% FBS,
0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24 hours. Percent viability was determined through
CellQuanti-Blue™ cell viability assay after 96-hour treatment with 0-1500 µM TMZ. Reported values indicate the
mean of three replicates converted to percent of control (media only) in Prism software. Reported values presented
as dose-response curve using Prism software.
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Figure 20. ß-HB supplementation further sensitizes T98G cells cultured under normal glucose media to
temozolomide. Human GBM cell line T98G were tested for TMZ sensitivity under normal glucose media plus ßHB. Cells were plated at 5,000 cells per well and incubated in normal glucose media (Black, 2.0 g/L glucose) or
normal glucose media plus ß-HB (Red, 2.0 g/L glucose + 2.0 mM ß-HB) DMEM supplemented with 10% FBS, 0.29
g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24 hours. Percent viability was determined through CellQuantiBlue™ cell viability assay after 96-hour treatment with 0-1500 µM TMZ. Reported values indicate the mean of
three replicates converted to percent of control (media only) in Prism software. Reported values presented as doseresponse curve using Prism software.

54

Effects of glucose restriction conditions plus ß-HB in combination with temozolomide in human astroglial
cell line
In contrast to GBM cell lines, glucose restricted media plus ß-HB cytotoxicity to TMZ in SVG
p12 cells. The IC50 value increased from 77.2 µM to 92.8 µM when SVG p12 cells were cultured in
glucose restricted media plus ß-HB (p <0.001), suggesting a protective effect (Table 1) (Figure 21). Using
the data from the previous chapter, we again compared the effects of TMZ under glucose restriction
conditions and normal glucose media, to their respective counterparts containing ß-HB in SVG p12 cells.
The IC50 value of TMZ increased from 92.80 µM to 246.1 µM when SVG p12 were cultured under
glucose restriction plus ß-HB (p <0.001) (Table 1) (Figure 22). The IC50 value of TMZ increased from
77.19 µM to 187.8 µM when T98G were cultured under normal glucose media plus ß-HB (p <0.001)
(Table 1) (Figure 23).
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Figure 21. Glucose restricted media supplemented with ß-HB has slight protective effects on SVG p12 normal
astroglial cells sensitivity to temozolomide. Normal human astroglial cell line SVG p12 were tested for TMZ
sensitivity under glucose restricted media supplemented with ß-HB. Cells were plated at 5,000 cells per well and
incubated in glucose restricted media plus ß-HB (Red, 0.5 g/L glucose + 2.0 mM ß-HB) or normal glucose media
plus ß-HB (Black, 2.0 g/L glucose + 2.0 mM ß-HB) DMEM supplemented with 10% FBS, 0.29 g/L L-glutamine,
and 0.11 g/L sodium pyruvate for 24 hours. Percent viability was determined through CellQuanti-Blue™ cell
viability assay after 96-hour treatment with 0-1500 µM TMZ. Reported values indicate the mean of three replicates
converted to percent of control (media only) in Prism software. Reported values presented as dose-response curve
using Prism software.
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Figure 22. ß-HB supplementation protects SVG p12 cells cultured under glucose restricted media to
temozolomide. Human astroglial cell line SVG p12 were tested for TMZ sensitivity under normal glucose media
(A) or restricted glucose conditions (B) with or without ß-HB supplementation. (A) SVG p12 cells were plated at
5,000 cells per well and incubated in low glucose DMEM (Black, 0.5 g/L glucose) or low glucose DMEM plus 2.0
mM ß-HB (Red, 0.5 g/L glucose + 2.0 mM ß-HB) for 24 hours. Percent viability was determined through
CellQuanti-Blue™ cell viability assay after 96-hour treatment with 0-1500 µM TMZ. Reported values indicate the
mean of three replicates converted to percent of control (media only) in Prism software. Reported values presented
as dose-response curve using Prism software.

57

SVGp12

100

Viability %

75
50
25

2.0 g/L glucose + 2.0 mM ß-HB
2.0 g/L glucose

0
0

1

2

3

Log[Temozolomide]
Figure 23. ß-HB supplementation protects SVG p12 cells cultured under normal glucose media to
temozolomide. Human astroglial cell line SVG p12 were tested for TMZ sensitivity under normal glucose media
plus ß-HB. Cells were plated at 5,000 cells per well and incubated in normal glucose media (Black, 2.0 g/L glucose)
or normal glucose media plus ß-HB (Red, 2.0 g/L glucose + 2.0 mM ß-HB) DMEM supplemented with 10% FBS,
0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate for 24 hours. Percent viability was determined through
CellQuanti-Blue™ cell viability assay after 96-hour treatment with 0-1500 µM TMZ. Reported values indicate the
mean of three replicates converted to percent of control (media only) in Prism software. Reported values presented
as dose-response curve using Prism software.
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Discussion
Glucose restriction plus ß-HB enhanced the efficiency of TMZ in both GBM cell lines LN229
and T98G. In LN229, the IC50 value decreased from 189.1 µM to 76.66 µM, a 59.5% decrease, when
cultured under glucose restricted media plus ß-HB (p <0.001) (Table 1) (Figure 15). In T98G cells, the
IC50 value decreased from 442.3 µM to 177.1 µM, a 60.0% decrease, when cultured under glucose
restricted media plus ß-HB (p <0.001) (Table 1) (Figure 18). Therefore, the hypothesis that exposure to
glucose restricted media plus ß-HB prior to and during TMZ treatment would further sensitize GBM cells
to TMZ is supported.
In contrast to GBM cells, glucose restricted media plus ß-HB slightly reduced the efficiency of
TMZ in normal human astroglial cell line SVG p12. In SVG p12 cells, the IC50 value of TMZ increased
from 187.8 µM to 246.1 µM, a 31.0% increase, when cultured under glucose restricted media plus ß-HB
(p <0.001) (Table 1) (Figure 21). The change in IC50 indicates that more drug is necessary to kill the
same number of cells when SVGp12 cells are cultured under glucose restricted media plus ß-HB. Thus,
the hypothesis that exposure to glucose restricted media plus ß-HB prior to and during treatment would
protect normal astroglial cells from the cytotoxic effects of TMZ was supported.
The statistical analysis between TMZ induced cytotoxicity of LN229 cells cultured under glucose
restricted media (chapter 5) verse glucose restricted media plus ß-HB produced conflicting results. The
IC50 value of TMZ decreased from 85.29 µM to 76.66 µM, a 10.1% decrease, when cultured under
glucose restricted media plus ß-HB (NS) (Table 1) (Figure 16). However, this change in IC50 value was
found to be not significant. Comparison of normal glucose media (chapter 5) to normal glucose media
plus ß-HB suggest ß-HB enhances the cytotoxic effects of TMZ in LN229 cells. The IC50 value of TMZ
decreased from 273.5 µM to 189.1 µM, a 30.9% decrease, when cultured under normal glucose media
plus ß-HB (p =0.0243) (Table 1) (Figure 17). These results suggest under normal media conditions, ß-HB
enhances the cytotoxic effects of TMZ in LN229 cells.
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The statistical analysis between TMZ induced cytotoxicity of T98G cells under glucose restricted
media (chapter 5) verse glucose restricted media plus ß-HB suggests ß-HB sensitizes T98G cells to TMZ.
The IC50 value of TMZ decreased from 371.4 µM to 177.1 µM, a 52.3% decrease, when cultured under
glucose restricted media plus ß-HB (p <0.001) (Table 1) (Figure 19). This drop in IC50 value suggests
that ß-HB enhances the cytotoxic effects of TMZ in T98G cells cultured under glucose restricted media.
The IC50 value of TMZ decreased from 678.3 µM to 442.3 µM, a 34.8% decrease, when cultured normal
glucose media plus ß-HB (p =0.0043) (Table 1) (Figure 20). This drop in IC50 value suggests that ß-HB
enhances the cytotoxic effects of TMZ in T98G cells cultured normal glucose media. Taken all together,
these results suggest that ß-HB enhances the cytotoxic effects of TMZ in T98G cells.
In contrast to GBM cell lines, statistical analysis between TMZ induced cytotoxicity of normal
astroglial cell line SVG p12 under glucose restricted media (chapter 5) verse glucose restricted media plus
ß-HB suggests ß-HB protects SVG p12 cells to TMZ. The IC50 value of TMZ increased from 187.8 µM
to 246.1 µM, a 165.19% increase, when cultured under glucose restricted media plus ß-HB (p <0.001)
(Table 1) (Figure 22). This increase in IC50 suggests ß-HB decreases the cytotoxic effects of TMZ in
SVG p12 cells cultured under glucose restricted media. The IC50 value of TMZ decreased from 77.19
µM to 187.8 µM, a 143.3% increase, when cultured under normal glucose media plus ß-HB (p <0.001)
(Table 1) (Figure 23). This increase in IC50 suggests ß-HB decreases the cytotoxic effects of TMZ in
SVG p12 cells cultured under glucose restricted media. Taken all together, these results suggest that ß-HB
protects SVG p12 cells from the cytotoxic effects of TMZ.
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CHAPTER 7: ANALYZING THE EFFECTS OF GLUCOSE RESTRICTED MEDIA AND βHYDROXYBUTYRATE IN COMBINATION TEMOZOLOMIDE ON MGMT EXPRESSION IN GBM
AND HUMAN ASTROGLIAL CELLS.
Introduction
Temozolomide (TMZ) is the standard chemotherapy agent for the treatment of glioblastoma
multiforme (GBM). GBM cells expressing the DNA repair protein O6-methyl-guanine-DNA
methyltransferase (MGMT) are resistant to the TMZ induced cytotoxic lesions. Fasting induces systemic
changes such as reducing anabolic hormones, reducing systemic glucose concentration, and the
production of ketone bodies (KB). KB are hepatically produced and systemically released molecules that
serve as an energy source for the heart, skeletal muscle, kidney, and brain.31–35 Fasting has been
previously shown to protect normal cells while sensitizing cancer cells to chemotherapy, a phenomenon
known as the differential stress response (DSR).
The previous chapters showed glucose restricted media enhanced the cytotoxicity of TMZ in
LN229 and T98G GBM cells, while having no effect in SVG p12 normal astroglial cells. Furthermore,
glucose restricted media plus ß-hydroxybutyrate (ß-HB), a ketone body, further enhanced the cytotoxic
effects of TMZ in LN229 and T98G cells, while having protective effects in SVG p12 cells. However, the
mechanism by which glucose restricted media plus ß-HB can induce DSR to TMZ remains to be
determined. The experiments in this chapter were designed to analyze the effects glucose restriction
media, and glucose restricted media plus ß-HB, in combination with TMZ has on the expression of
MGMT in GBM cell lines, LN229 and T98G, and a normal astroglial cell line, SVG p12. Western
analysis showed T98G were the only cell line that expressed MGMT. In T98G, the data indicates that
glucose restricted media led to a decrease in MGMT levels. Furthermore, glucose restriction plus ß-HB
further decreased MGMT levels in T98G cells. Thus, the mechanism by which glucose restricted media
enhances the cytotoxic effects of TMZ in T98G cells could be by decreasing MGMT levels.
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Materials and Methods
Preparation of Cell Culture Medium: Normal glucose media, DMEM containing 2.0 g/L D-(+)glucose (Sigma-Aldrich), 0.29 g/L L-glutamine (Gibco), 0.11 g/L sodium pyruvate (Gibco), and 10%
FBS (Atlanta Biological), was prepared as stated previously. Glucose restricted media was prepared
through a 1:3 dilution of the normal glucose media into glucose-free DMEM containing 0.29 g/L Lglutamine (Gibco), 0.11 g/L sodium pyruvate (Gibco), and 10% FBS (Atlanta Biological). The final
concentration glucose restricted media was 0.5 g/L g/L D-(+)-glucose. For ß-HB conditions, sodium ßHB (Millipore Sigma) was dissolved into normal glucose media and glucose restricted media to a
concentration of 2.0 mM.
Preparation of Temozolomide: Temozolomide (TMZ) was purchased from Sigma-Aldrich (St.
Louis, MO) and dissolved into glucose restricted media, glucose restricted media plus 2.0 mM ß-HB,
normal glucose media, and normal glucose media plus 2.0 mM ß-HB to a concentration of 1000 µM. To
ensure complete solubility of TMZ in DMEM, the solution was vortexed at maximum speed. Working
concentrations were prepared equal to the IC50 value [µM] for each treatment condition, in each cell line.
Amount of stock TMZ in DMEM (V1) [µL]to add was determined by dividing the product of IC50 (C2)
[µM] and total volume of 20 mL [20,000 µL] by the concentration of the TMZ stock [1000 µM] (equation
3). Summary of IC50 values can be seen in table 1.
Cell Line Culture: Cells were cultured in DMEM as previously discussed. Briefly, cells were
detached from flasks using trypsin-EDTA, pelleted by centrifugal force, and resuspended into one mL of
DMEM. Cell count of cell suspension was subsequently done using trypan-blue exclusion method.
Appropriate amount of cell suspension was added to a conical tube containing DMEM to achieve a final
concentration of 200,000 cells/mL and seeded 2,000,000 cells/flask (10 mL) into T-75 tissue culture
treated flask (ThermoFisher Scientific). Cells were incubated under standard conditions and media was
changed every second day.
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Once cells reached approximately 80% confluency, the original complete medium was carefully
removed, washed with Dulbecco’s Phosphate Buffered Saline (DPBS) (Sigma-Aldrich), and replaced
with either glucose restricted media, normal glucose media, glucose restricted media plus 2.0 mM ß-HB,
normal glucose media plus 2.0 mM ß-HB, or positive control media (DMEM; 4.5 g/L D-(+)-glucose, 10%
FBS, 0.29 g/L L-glutamine, and 0.11 g/L sodium pyruvate) for 24 hours. After 24 hours, media was
removed, washed with (DPBS), and replaced with respective media conditions containing the IC50 value
for each cell line or DMEM. Plates were sustained in standard incubation conditions. After 48 hours of
treatment, cells received an additional 5 mL of their respective TMZ media conditions. Treatment lasted a
total of 96 hours.
Preparation and quantification of cell lysates. Following 96 hours of treatment, media was
removed and collected in a 50 mL conical tube. Cells were washed with DPBS, enzymatically
disassociated from the flask using Trypsin/EDTA (Gibco), added to their respective conical tube, and
centrifuged at 280 rcf for three minutes. Supernatant was carefully removed, and pellet was resuspended
in 1 mL of cold DPBS (4°C). Cell count of cell suspension was subsequently done using trypan-blue
exclusion method. Cell suspensions were transferred into labeled 1.5 mL Eppendorf tubes and centrifuged
at 280 rcf for 3 min at 4°C. Supernatant was carefully removed, and cells were resuspended in appropriate
amounts of cold radioimmunoprecipitation assay (RIPA) buffer (Cell Signaling Technology, Danvers,
MA) to achieve a concentration of 20,000 cells/µL RIPA. RIPA buffer is a lysis buffer that is used to
solubilize cellular proteins for subsequent analysis. Cells lysates were gentle agitated using a
micropipettor and placed on ice for 10 min. Agitation of cell lysate was repeated every 10 min for a total
of 30 min. After 30 min, insoluble material was pelleted by centrifuging samples at 15,000 rcf for 15 min
at 4 °C. Supernatants were carefully removed using a micropipettor and placed into labeled 1.5 mL
Eppendorf tubes on ice.
Following removal of supernatant, protein concentration of lysates was immediately quantified
using a PierceTM bicinchoninic acid (BCA) protein assay kit (Thermo Scientific) per manufactural
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protocol. Briefly, cell lysates were diluted 1:4 and 1:8 in RIPA. Diluted samples (25 µL) were placed into
a 96 well microplate in triplicate. Bovine serum albumin (BSA) standard samples (25 µL) ranging from
2000 µg/mL to 25 µg/mL were also added to the 96 well microplate. BCA solution (200 µL) was added
to each well and incubated at 37 °C for 30 min. BCA solution contains copper (II) sulfate. Cu2+ ions are
reduced by the peptide bods present in proteins. Thus, the amount of Cu2+ ions reduced is directly
proportional to the concentration of protein in each sample. Subsequent chelation between two molecules
of BCA and one reduced Cu2+ ion produces a purple complex that absorbs light at a wavelength of 562
nm. Following 30 min of incubation, absorbance of each well was read using Modulus II Microplate
Reader (Turner Biosystems) at a wavelength of 560 nm. The average absorbance of each known BSA
standard was calculated and a standard curve of absorbance as a function of protein concentration (µg/µL)
was generated fit to linear regression model in excel. The slope of this resulting graph was subsequently
used to determine the concentration of protein (µg/mL) in the cell lysates.
Western blot analysis. Treated LN229, T98G, and SVG p12 cell lysates were diluted using of
Laemmli Sample Buffer (15.6 mM Tris-HCl, 355 mM ß-mercaptoethanol, pH 6.8, 10% glycerol, 1%
SDS, 0.005% bromophenol blue) so that 35 µg of protein was loaded into each well of a 4-20% MidiPROTEAN® TGX Stain-Free™ gel (Bio-Rad). Samples were heated at 90 °C for 5 min to denature
proteins. Proteins were separated by size using SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Protein ladder containing 1:1 dilution of Precision Plus Protein Unstained (Bio-Rad Laboratories,
Hercules, CA) and All Blue Standard (Bio-Rad) was used as molecular weight indicator. Protein gels
were subjected to electrophoresis at a constant 150 V with varying current for one hour at 4 °C.
Following electrophoresis, proteins were transferred onto 0.2 µm nitrocellulose membrane (BioRad) using the Trans-Blot® Turbo Transfer System™ (Bio-Rad) at a constant 1.3 A with varying voltage
for 7 min. Blots were blocked with a 5% non-fat dry milk (NFDM) in tris-buffered saline plus 0.1%
Tween-20 (TBST) (20 mM Tris base, 150 mM NaCl, 0.1% v/v Tween-20) for 90 min at RT with gentle
agitation, and subsequently washed with TBST. Anti-MGMT Monoclonal Antibody (Invitrogen,
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Carlsbad, CA) (1:100) and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Monoclonal
Antibody (Invitrogen) (1:40,000) in 2.5% NFDM-TBST was added overnight at 4 °C with gentle
agitation. The membrane was washed again with TBST and incubated with Goat anti-Mouse IgG (H+L)
Secondary Antibody, HRP (Invitrogen) (1:10,000) in 2.5% NFDM-TBST for 40 min at RT. Blots were
washed a final time with TBST, followed by detection with Clarity™ Western ECL Substrate (Bio-Rad).
Chemiluminescent image was acquired using ChemiDoc™ MP Imaging System (Bio-Rad).
Statistical Analysis: Acquired images of western blots were analyzed using ImageLabTM Software
(Bio-Rad). Relative expression of MGMT between three replicates was determined by normalizing the
optical density (OD) of MGMT bands against GAPDH bands. Comparison of the effects of glucose
restricted media, normal glucose media, glucose restricted media plus ß-HB, and normal glucose media
plus ß-HB on expression of MGMT was found by plotting the average relative MGMT expression
between three replicates against their respective treatment condition fit to a group column analysis in
Prism 5 (GraphPad Software). Statistical significance between each treatment group was analyzed
through one-way ANOVA in Prism 5 (GraphPad Software). Significance was denoted to one asterisk (*)
if p<0.05, two (**) if p<0.01, and three (***) if p<0.001. All data presented show the standard deviation
of the mean (SD).

𝑉1 =

𝐶2 × 20,000 µ𝐿)
1000 µ𝑀

Equation 3. Determining the amount of stock TMZ in DMEM needed to achieve working
concentration. Working concentration were made for each cell line under each media condition equal to
their respective IC50 value. Equation 3 describes the amount of stock TMZ in DMEM (V1) [1000 µM]
needed to achieve the respective IC50 value. V1 [µL] was determined by dividing the product of IC50
(C2) [µM] and total volume [20,000 µL] by the concentration of the TMZ stock [1000 µM].
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Results
Effects of glucose restricted media in combination with TMZ on the expression of MGMT in GBM cell
lines and normal astroglial cell line.
We sought to determine the effect of glucose restricted media in combination with TMZ on the
expression of MGMT in GBM cell lines, LN229 and T98G, and a normal human astrocyte cell line, SVG
p12. As described earlier, cells were incubated in low glucose media (0.5 g/L) or normal glucose (2.0 g/L)
DMEM supplemented with 2.0 mM ß-HB for 24 hours prior to, and during treatment with TMZ.
Following 96 hours of TMZ treatment, cell lysates were generated, proteins separated by SDS-PAGE,
transferred to nitrocellulose blot, and MGMT and GAPDH expression was detected using antibodies. Of
cell lines tested, T98G were the only one that expressed the MGMT protein (Figure 24). The results from
a 96-hour treatment with TMZ in T98G cells indicate that glucose restricted media downregulates the
expression of MGMT (Figure 24A). The relative expression of MGMT decreased from 0.4044 to 0.2924
when T98G cells were cultured in glucose restricted conditions (p <0.01) (Figure 24B).
Effects of glucose restricted media plus ß-HB in combination with TMZ on the expression of MGMT in
GBM cell lines and normal astroglial cell line.
We sought to determine the effect of glucose restricted media plus ß-HB in combination with
TMZ on the expression of MGMT in GBM cell lines, LN229 and T98G, and a normal human astrocyte
cell line, SVG p12. As described earlier, cells were incubated in glucose restricted media plus ß-HB (0.5
g/L glucose + 2.0 mM ß-HB) or normal glucose media plus ß-HB (2.0 g/L glucose + 2.0 mM ß-HB) for
24 hours prior to, and during treatment with TMZ. Following 96 hours of TMZ treatment, cell lysates
were generated, proteins separated by SDS-PAGE, transferred to nitrocellulose blot, and MGMT and
GAPDH expression was detected using antibodies. Of cell lines tested, T98G were the only one that
expressed the MGMT protein (Figure 24). The results from a 96-hour treatment with TMZ in T98G cells
indicate that glucose restricted media plus ß-HB downregulates the expression of MGMT (Figure 24).
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The relative expression of MGMT decreased from 0.3365 to 0.2457 when T98G cells were cultured in
glucose restricted media plus ß-HB (p <0.01) (Figure 24B).
We compared the effects of TMZ under glucose restriction conditions and normal glucose media,
to their respective counterparts containing ß-HB on the expression of MGMT in T98G cells. The results
from a 96-hour treatment with TMZ in T98G cells indicate that ß-HB downregulates the expression of
MGMT under normal glucose media (Figure 24). The relative expression of MGMT decreased from
0.4044 to 0.3365 when T98G cells were cultured in normal glucose media plus ß-HB (p <0.05) (Figure
24B). The ratio of MGMT:GAPDH also decreased from 0.2924 to 0.2457 when T98G cells were cultured
in glucose restricted media plus ß-HB (NS) (Figure 24B). However, no significance was noted between
glucose restricted media and glucose restricted media plus ß-HB with respect to MGMT:GAPDH ratio.
Further comparison was done between the effects of TMZ under glucose restricted media plus ßHB to the effects of TMZ under normal glucose media on expression of MGMT in T98G cells. The
results from a 96-hour treatment with TMZ in T98G cells indicate that glucose restricted media plus ß-HB
downregulates the expression of MGMT (Figure 24). The relative expression of MGMT decreased from
0.4044 to 0.2457 when T98G cells were cultured in normal glucose media plus ß-HB (p <0.001) (Figure
24B).
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Figure 24. Glucose restricted media and glucose restricted media plus ß-HB in combination with TMZ
downregulates MGMT expression in T98G cells. The effects of glucose restricted media and ß-HB in
combination with TMZ on the expression of MGMT was analyzed in GBM cell lines, LN229 and T98G, and human
astroglial cell line, SVG p12. Cells were exposed to glucose restricted media (0.5 g/L glucose), normal glucose
media (2.0 g/L glucose), glucose restricted media plus ß-HB (0.5 g/L glucose + 2.0 mM ß-HB), or normal glucose
media plus ß-HB (2.0 g/L glucose + 2.0 mM ß-HB) for 24 hours. Lysates were prepared after 96-hour treatment
with respective TMZ IC50 value for each cell line as described in the Materials and Methods. Proteins were
separated through SDS-PAGE on 4-20% Midi-PROTEAN® TGX Stain-Free™ gels, transferred onto 0.2 µm
Nitrocellulose, incubated with anti-MGMT and anti-GAPDH primary antibodies, and incubated with goat antiMouse secondary antibody. (A) Chemiluminescent images of LN229, T98G, and SVGp12 lysates under the four
different media conditions. (B) Reported values of the average ratio of MGMT (23 kDA) OD to GAPDH (37 kDa)
OD between three replicates in T98G cells presented as group column analysis using Prism software. All data
presented as mean (SD); * p<0.05, ** p<0.01, *** p<0.001, one-way ANOVA.
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Discussion
Of the two GBM cell lines, LN229 and T98G, and the normal astroglial cell line, SVG p12, T98G
was the only cell line that expressed the MGMT protein. The blots containing T98G cell lysate were the
only blots in which a band was produced at 23 kDa, indicating the presence of MGMT (Figure 24A).
Glucose restricted media in combination with TMZ decreases MGMT levels in T98G cells. In
T98G, the relative expression of MGMT decreased from 0.4044 to 0.2924, a 27.7% decrease, when
cultured under glucose restricted media (p <0.01) (Figure 24B). Due to the function of MGMT in TMZ
resistance, decreasing MGMT levels would lead to increased efficiency in cytotoxicity of TMZ. Thus, the
enhanced cytotoxicity of TMZ in T98G cells cultured under glucose restricted media could be due to the
decrease in MGMT levels.
Glucose restricted media plus ß-HB in combination with TMZ decreases MGMT levels in T98G
cells. In T98G, the relative expression of MGMT decreased from 0.3365 to 0.2457, a 27.0% decrease,
when cultured under glucose restricted media plus ß-HB (p <0.01) (Figure 24B). Thus, it is likely that the
enhanced cytotoxicity of TMZ in T98G cells cultured under glucose restricted media plus ß-HB is due to
the decrease in MGMT.
Comparison of MGMT expression under normal glucose media to normal glucose media plus ßHB suggests ß-HB alone leads to the decreases MGMT levels in T98G cells. In T98G, the relative
expression of MGMT decreased from 0.4044 to 0.3365, a 16.8% decrease, when cultured under normal
glucose media plus ß-HB (p <0.01) (Figure 24B). Comparison of the expression of MGMT in T98G
cultured under glucose restricted media to MGMT expression under glucose restricted media plus ß-HB
showed slight reduction in MGMT levels. In T98G, the relative expression of MGMT decreased from
0.2924 to 0.2457, a 16.0% decrease, when cultured under glucose restricted media plus ß-HB (NS)
(Figure 24B). However, this 16.0% decrease in MGMT expression under glucose restricted media plus ßHB was found to be not significant. Taken all together, these results suggest ß-HB leads to the decrease of
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MGMT in T98G cells. Thus, it is likely that the enhanced cytotoxicity of TMZ in T98G cells by ß-HB is
due to ß-HB a reduction in MGMT.
Comparison of MGMT expression under normal glucose media to glucose restricted media plus
ß-HB suggests glucose restriction media plus ß-HB leads to robust reduction of MGMT in T98G cells. In
T98G, the relative expression of MGMT decreased from 0.4044 to 0.2457, a 39.2% decrease, when
cultured under glucose restricted media plus ß-HB (p <0.001) (Figure 24B). Thus, it is likely that the
enhanced cytotoxicity of TMZ in T98G cells by glucose restricted media ß-HB is due to reduction in
MGMT levels.
As previously discussed, fasting induces systemic changes such as reducing anabolic hormones,
reducing systemic glucose concentration, and the production of KB. Glucose restricted media plus ß-HB
was used in these experiments to mimic the drop in blood glucose and the increase in KB that occurs
during fasting. Normal glucose media was used in these experiments to mimic the conditions that occur
during ad-lib feeding. The most profound statistical in MGMT expression difference between treatment
groups was found when comparing the effects of normal glucose media and glucose restricted media plus
ß-HB (p <0.001) (Figure 24B). Thus, these results suggest that fasting may be a useful treatment fasting
may be a useful increase cytotoxicity of TMZ in GBM cells expressing MGMT.
Due to the role of MGMT in TMZ resistance, the reduction of MGMT provides an explanation by
which ß-HB enhanced the cytotoxicity of TMZ in T98G. However, the mechanism by which ß-HB
reduces MGMT levels in T98G cells remains to be determined. One such hypothesis by ß-HB reduces
MGMT levels in T98G cells is through ß-HB effects on HDAC. As discussed previously, HDAC are
nuclear enzymes that function in epigenetic modifications through chromatin remodeling. HDACs are
divided into four classes based on their homology to proteins isolated from yeast. Class I HDAC,
including HDAC1, HDAC2, HDAC3, and HDAC8 share homology to yeast RPD3. HDAC8 is
ubiquitously expressed but is highly abundant in the prostate, kidney, and brain.96 HDAC8 interaction
with the proteasomal ubiquitin receptor ADRM1 has been previously shown to regulate MGMT
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expression in GBM cell line T98G. In this study, treatment with the selective HDAC8 inhibitor PCI34051
led to a decrease in MGMT levels, increased TMZ-induced DNA damage, induced cell cycle arrest, and
decreased cell viability of T98G cells.98 n-Butyrate is an endogenous four carbon chain fatty acid
produced by the gut microbiome during bacterial fermentation of carbohydrates. n-Butyrate is a well
characterized inhibitor of class I HDACs.99 Inhibition occurs due to Class I HDACs binding affinity to
carbonic acid side chains of butyrate. Treatment with n-butyrate has antiproliferative effects in leukemia,
breast cancer, and colorectal cancer cells through its inhibition of HDAC8 activity.100–102 Unfortunately,
the short half-life and high hepatic clearance dampens the antiproliferative effects in vivo.103–105 Differing
from n-butyrate by a single hydroxy group, ß-HB has also been shown to have inhibitory effects on Class
I HDACs. It is possible that ß-HB inhibits HDAC8 to reduce MGMT levels in T98G cells. However,
future studies on the effects of ß-HB on HDAC8 activity and MGMT regulation is needed to determine
the mechanism by which ß-HB reduces MGMT in T98G cells.
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CHAPTER 8: SUMMARY AND CONCLUSIONS

GBM is the most common and deadly primary brain tumor in adults. The standard of care for
GBM is maximal surgical resection of the tumor followed by adjuvant treatment with the
chemotherapeutic agent temozolomide (TMZ) and radiotherapy. Despite advancements in surgical
procedures, chemotherapeutics, and radiotherapy, the prognosis for GBM remains dismal. The Warburg
effect describes a common trait of cancer in which cancer cells preferentially oxidize glucose to lactate in
glycolysis, inhibiting mitochondrial respiration. To meet physiological needs, cancer cells must oxidize
significantly greater amounts of glucose. One method that directly targets the bioavailability of glucose is
fasting. Fasting leads to rapid reduction of plasma glucose, reduction of anabolic hormones, and
production of KB. Normal cells respond to these changes by reinvesting energy towards
repair/maintenance/survival. Cancer cells harbor oncogenic mutations that hinders their ability to adjust to
such changes. The DSR induced by fasting has been shown to protect normal cells while sensitizing
cancer cells to chemotherapy.26,28,29
Summary of the effects of fasting in combination with TMZ the viability and expression of MGMT in GBM
and normal glial cell lines.
This thesis sought to evaluate the effects fasting in combination with TMZ in human GBM cell
lines, LN229 and T98G, and a normal astroglial cell line, SVG p12. Exposure of LN229 and T98G to
glucose restricted media prior to and during treatment enhanced the cytotoxic effects of TMZ, while
showing no effect in SVGp12 cells. Furthermore, exposure of LN229 and T98G to glucose restricted
media plus ß-HB prior to and during treatment led to greater enhancement of the cytotoxic effects of
TMZ, while having protective effects in SVG p12 cells. We then sought to determine the effect of glucose
restricted media and ß-HB on the expression of MGMT, a gene that functions in the removal of TMZ
induced O6MeG cytotoxic lesions. Of all three cell lines tested, T98G were the only cell line that
expressed MGMT protein. Exposure of T98G cells to glucose restricted media in combination with TMZ
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lead to the downregulation of MGMT. Moreover, exposure of T98G cells to glucose restricted media plus
ß-HB led to further downregulation of MGMT. Thus, this study provided evidence for the use of fasting
as an adjuvant therapy in the treatment of GBM.
Overview of study limitations and future directions.
Several limitations existed within the described experiments. As discussed earlier, the reduction
of nutrient availability during fasting leads to numerous systemic alterations. Fasting induces the
mobilization of fatty acids from adipose tissue, leading to increased plasma free fatty acid (FFA)
concentrations. Fasting also induces reduction of anabolic hormones, such as insulin and IGF-1, and the
release of catabolic hormones, such as epinephrine, glucagon, and cortisol. The media conditions of this
study only accounted for two fasting induced adaptations, the reduction of glucose and the increase of ßHB. Future studies that account for additional fasting induced adaptations are needed to fully evaluate the
potential of fasting as a therapy for GBM.
The choice of cell lines and the matrix by which they were grown in these experiments imposed
several study limitations. All cell lines used were previously established cell lines. Both LN229 and T98G
GBM cell lines were established in 1979.96,106 Over this period of 41 years, these cells have become
acclimated to life in culture. This has led to genomic alterations, such as chromosomal
deletions/amplifications and gene expression profiles, that are exclusively present in GBM established
cell lines. 107 Furthermore, T98G cells are no longer tumorigenic, that is they will not propagate in model
organisms. These changes suggest that established GBM cell lines poorly represent the nature of primary
GBM. Human diploid cells are restrained to a finite number of cellular divisions before entering
replicative senescence.108,109 SVG p12 is an astroglial cell line established in 1985 from 8-12-week-old
human fetal glial cells immortalized through transfection with mutant simian vacuolating virus 40
(SV40).110 Even though SVG p12 is not cancerous, SV-40 transformation allowing continuous
replication has caused SVG p12 to lose much of their in vivo characteristics. There is also evidence that
SVG p12 is contains an infectious BK polyomavirus.111 All cell lines were grown adherently as a
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monolayer in tissue culture treated vessels. This two-dimensional method of cell culture does not
accurately model the three-dimensional microenvironment of a tumor. Recent advancements in cell
culture techniques have led to the development of artificial three-dimensional cerebral organoids that
better represent in vivo GBM microenvironment.112 Therefore, future studies evaluating the effects of
fasting using three-dimensional models of patient derived GBM cell lines is warranted.
We used western blot analysis to evaluate the effects of glucose restriction and ß-HB in
combination with TMZ on the expression of MGMT. In doing so, we were only able to determine the
relative amount of MGMT present in each cell line at the protein level. MGMT becomes inactive
following the transfer of the methyl adduct from O6MeG, and this inactivation leads to the subsequent
proteasomal degradation of MGMT. Thus, MGMT is a suicide enzyme that requires de novo synthesis for
enzymatic recovery.113 The mechanism by which the relative amount of MGMT decreased in response to
both glucose restriction and ß-HB in T98G cells, whether it be through increased consumption or
transcriptional regulation, remains unknown. One way to determine this mechanism could be through
performing RT-qPCR. By quantifying the relative amount of MGMT mRNA transcripts, RT-qPCR would
show if the downregulation of MGMT was due to increased consumption or transcriptional regulation.
Overview of the clinical use of fasting and ketogenic metabolic therapies as an adjuvant therapy for
cancer and GBM .
The clinical use of fasting as an adjuvant therapy has been evaluated in a variety of cancers. A
pilot trial of 20 subjects evaluating short-term fasting (72 hour) in combination with platinum-based
chemotherapy found fasting to be safe and feasible. Over the 72-hour period, levels of blood glucose,
insulin, IGF-1, and ß-HB were monitored. Although reduction in insulin, IGF-1, and glucose and increase
in ß-HB were found over the first 24-48 hours, the lack of continuing changes in glucose and ß-HB levels
may indicate some subjects did not successfully complete the full 72 hour fast.114 Other studies evaluating
the effects of short-term fasting on quality of life and tolerance to chemotherapy in breast and ovarian
cancer patients found short-term fasting improved quality of life and fatigue related symptoms during
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chemotherapy.106,107 These studies support the safety and feasibility of fasting in combination with
chemotherapy for the treatment of GBM.
Although no studies have evaluated the use of fasting for the treatment GBM, there are various
clinical studies evaluating ketogenic metabolic therapies (KMT) as adjuvants to standard GBM treatment.
These studies implemented a diet designed to mimic some the effects of fasting called the ketogenic diet
(KD).Created and put into practice in 1921 for the treatment of epilepsy, the KD features nutrient intake
divided into of no-to-low carbohydrate (0-5%), moderate protein (30-45%), and high amounts of fat (6065%).117–119 Similar to fasting, KD forces the body to rely on endogenous glucose production. However,
the rate at which glucose is synthesized endogenously is not sufficient for the body’s physiological needs.
In response, the production of ketone bodies in the liver occurs through ketogenesis as an alternative
source of energy for the body.11 A pilot study evaluating the effects of the KD during treatment of
recurrent glioblastoma found it to be well tolerated, with 17 of 20 subjects (85%) following the diet on
average of 6.8 days per week. Of those 17 subjects, regular urine KB and blood glucose analysis was
available in 13 subjects. Stable ketosis (>0.5 mM) was detectable in 12 of the 13 subjects (92%), but the
KD failed to significantly lower glucose levels (99 ± 21.8 to 9 2± 9.1). The median progression free
survival (PFS) was only 5 weeks and PFS at 6 months was 0%. There was no control group,
randomization, or adequate number of subjects to accurately estimate the efficiency of the KD.120 The
advantage of KD is patients are still able to intake food while still reaching a state of ketosis. The
disadvantage of KD is adequate protein intake provides substrates for gluconeogenesis, inhibiting the
reduction of blood glucose.
Other studies evaluating the effects of KMT as monotherapy for GBM have used a caloric
restricted KD. A case report of two GBM patients treated with and IRB-approved energy-restricted KD
(ERKD) as monotherapy found the ERKD to be safe and without major side effects. Both patients
presented with GBM, underwent standard therapies, and reached therapeutic failure (recurrence of
disease). Initiation of the ERKD therapy began with a supervised 48-hour water fast to induce ketosis,
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followed by ERKD protocol that was to be administered for 12 weeks. To evaluate diet adherence and
efficiency, body weight, blood glucose, and blood KB concentration were monitored daily using AM and
PM measurements, in which a goal of maintaining blood glucose levels of 50-70 mg/dL and blood KB
levels of 3-8 mM was defined. In Patient 1, an initial weight loss of 6% was seen followed by weight
stabilization during the first week of ERKD. Patient 1 PM KBs rose to >3 mM an PM KBs to > 2 mM,
where they remain for the duration of the study. However, Patient 1 AM and PM blood glucose levels
remained >80 mg/dL. After 4 weeks on the ERKD, patient 1 withdrew from the study due to impairment
of vision and cognition in which tumor growth was demonstrated within an MRI. In Patient 2, AM and
PM blood KBs rose to >3 mM where they remained for the duration of the study. However, Patient 2
blood glucose levels remained >100 mg/dl for the duration of the study. Six weeks after starting ERKD,
stable disease was demonstrated within the clinical exam and PET scan of patient 2. Unfortunately,
progression of disease was evident 12 weeks of after the start of ERKD. Unlike short term-fasting where
glucose levels can reach as low as 50-65 mg/dL, the inability of the ERKD to reduce and maintain
glucose levels between 50 to 70 mg/dL was cited as an explanation for the failure of ERKD to control
progression of disease. In addition, IHC analysis of key ketolytic enzymes BDH-1 and OXCT-1 in the
patients’ tumors showed diminished expression of BDH-1 and OXCT-1 in the original tumor of Patient 1.
However, subsequent biopsies showed positive expression of BDH-1 in Patient 1. In patient 2, positive
expression BDH1 and OXCT-1 were seen in the original tumor. These results suggest that these tumors
may possess the ability to metabolize KB for energy to be used during cellular growth.121
Future directions to evaluate the effects of fasting as an adjuvant therapy to the standard of care for
GBM in a clinical setting.
Our results suggest fasting can selectively enhance the cytotoxic effects of TMZ in GBM cells
while protecting astroglial cells. However, clinical studies are needed to determine the effects of fasting in
combination with TMZ for the treatment of GBM in patients. During concurrent chemotherapy and
radiotherapy, GBM patients are given TMZ 75 mg/m2 daily for up to 6 weeks. One month after
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completion of concurrent therapy, patients begin maintenance cycles lasting 6-12 months. The first cycle
is 28 days long and consists of TMZ 150 mg/m2 daily during days 1-5. The remaining 28-day cycles
consist of TMZ 200 mg/m2 daily during days 1-5. One potential study design could implement short-term
fasting (72-hour) as an adjuvant therapy during days 1-3 of the cycle. Another potential study design
could implement a short-term fast beginning 24-hours prior to day 1 and lasting through day 2 for the
entirety of the 28-day cycle. To maximize therapeutic efficiency, it is critical to determine the range of
blood glucose and KB concentration that has the strongest anti-tumor effect. Both studies should monitor
the relative blood insulin/IGF-1, glucose, and KB levels. These studies are needed to further assess the
potential of fasting as an adjuvant therapy in the treatment of GBM.
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